Bronchiolitis · Web of Medicine

On this page

Quick Reference

RxDrug of choiceSupportive care (oxygen, hydration, nasal suctioning), no specific drug of choice.

AltAlternativesHigh-flow nasal cannula (HFNC) for respiratory support; nirsevimab for prevention; ziresovir (experimental) for treatment.

⊘AvoidRoutine bronchodilators, corticosteroids, hypertonic saline, antibiotics, chest physiotherapy, caffeine citrate for apnea.

DxTest of choiceClinical diagnosis.

ScKey scoreRDAI (Respiratory Distress Assessment Instrument) or Wang bronchiolitis clinical score.

→When to referPersistent hypoxia despite oxygen, apnea, severe respiratory distress, inability to feed, comorbidities.

Supportive care is the mainstay; avoid unnecessary interventions; nirsevimab prevents severe disease.

Bronchiolitis is an acute viral lower respiratory tract infection in infants <2 years, primarily caused by [[respiratory syncytial virus]] (RSV), and is the leading cause of hospitalization in US infants <1 year, with over 149,000 admissions annually. The diagnosis is clinical, and management is entirely supportive, oxygen, nasal suctioning, and hydration, with no role for routine bronchodilators, corticosteroids, or antibiotics. High-flow nasal cannula reduces treatment failure in moderate-to-severe disease, and [[nirsevimab]] provides effective single-dose prevention for all infants. Most cases are self-limited, but severe disease can occur, particularly in young infants with comorbidities or those presenting with apnea.

Overview and Recommendations

Background

•Bronchiolitis is an acute viral lower respiratory tract infection in infants <2 years, characterized by inflammation, mucus plugging, and bronchiolar obstruction, most commonly caused by (RSV). It is the leading cause of hospitalization in US infants <1 year, accounting for over 149,000 admissions annually and $543 million in direct costs, though the majority of cases (87%) are managed in primary care.
•The pathophysiology centers on viral infection of the airway epithelium, leading to epithelial necrosis, neutrophil infiltration, and sloughed debris that obstruct small airways. The host immune response, particularly a >200-fold elevation of IL-6, drives the most severe outcomes, including rapid deterioration and brain edema in fatal cases.
•Risk factors for severe disease include age <2 months, preterm birth, congenital heart disease, chronic lung disease, immunodeficiency, siblings aged 0-3 years, low income, and neighborhood deprivation. The strongest predictor is the presence of any comorbidity (OR 5.33).
•The clinical course follows a catarrhal phase (rhinorrhea, cough, low-grade fever) over 1-2 days, then a respiratory distress phase (tachypnea, wheezing, hypoxemia) peaking at days 3-5, followed by gradual recovery. Apnea may be the sole presenting sign in infants <2 months.
•Bronchiolitis is defined as the first episode of wheezing in an infant <2 years; recurrent wheezing episodes should be labeled as asthma or recurrent viral wheeze, not bronchiolitis, to avoid unnecessary bronchodilator and corticosteroid use.

Evaluation

•Suspect bronchiolitis in any infant <2 years presenting with acute onset of coryza (rhinorrhea, nasal congestion, cough) followed by lower respiratory signs: tachypnea, wheezing, crackles, and increased work of breathing.
•Ask about the onset and progression of symptoms, fever, feeding intolerance (decreased oral intake, fewer wet diapers), apnea (especially in infants <2 months), and exposure to sick contacts or tobacco smoke.
•Examine for vital signs: respiratory rate >50-60/min, heart rate >160/min, SpO₂ <90% (or <87% in ED predicts ICU admission). Assess work of breathing, subcostal, intercostal, suprasternal retractions, nasal flaring, head bobbing, grunting. Auscultate for diffuse crackles and expiratory wheezes; in severe disease, breath sounds may be diminished due to air trapping.
•The gold-standard diagnostic test is clinical diagnosis: no laboratory or imaging test is required for confirmation in typical cases. The diagnosis rests on the presence of acute-onset lower respiratory illness with coryzal prodrome, tachypnea, and crackles/wheeze in a child ≤23 months.
•Do not routinely order chest radiography, it does not change management and increases antibiotic use. Reserve CXR for atypical presentations (suspected foreign body, pneumonia, atelectasis) or severe disease requiring ICU admission.
•Do not routinely obtain viral testing (e.g., RSV PCR), it does not alter management or outcomes. It may be used for cohorting hospitalized infants to prevent nosocomial spread, but this is a public health decision.
•Do not routinely obtain complete blood count, blood cultures, or inflammatory markers, they have no clinical utility in typical bronchiolitis. Procalcitonin and CRP may have some benefit in predicting bacterial co-infection in ICU patients, but evidence is very low.
•Consider urinalysis and urine culture only if there is clinical suspicion for UTI; the prevalence of concomitant UTI is only 3.1%, and drops to 0.8% when pyuria or nitrites are present, below recommended testing thresholds.
•Consider differential diagnoses: asthma (recurrent wheezing, older age, family atopy), (sudden choking, unilateral wheeze), (focal crackles, high fever, consolidation on CXR), (paroxysmal cough with whoop, post-tussive emesis, apnea, no fever), congenital heart disease (cyanosis, murmur, hepatomegaly).
•Use a severity score to objectify assessment: the (RDAI) (0-17) incorporates retractions, wheezing, and respiratory rate; the (0-12) includes respiratory rate, retractions, accessory muscles, and auscultation. Both have good interrater reliability but considerable measurement error (RDAI limits of agreement ±3.8 points), use the trend over 4-6 hours, not a single value.
•Risk stratify for severe outcomes: predictors of ICU admission include age <2 months, heart rate >160/min, SpO₂ <87%, previous ICU admission, and time of onset ≤2 days. The shows the highest discrimination for in-hospital mortality (AUROC 0.83) in resource-limited settings.
•In infants with comorbidities (prematurity, congenital heart disease, chronic lung disease, immunodeficiency), maintain a lower threshold for admission and escalation, odds of critical care admission or death after ED discharge are 5-fold higher.

Management

•Initiate supportive care as the cornerstone: oxygen therapy to maintain SpO₂ ≥90% (low-flow nasal cannula ≤2 L/min first-line), nasal suctioning (enhanced suctioning may reduce additional resource use), and hydration (enteral if safe, otherwise IV isotonic fluids).
•For mild disease (no hypoxia, mild respiratory distress, adequate feeding), manage at home with parental education on signs of deterioration and expected duration of cough (up to 3 weeks). Do not prescribe bronchodilators, corticosteroids, or antibiotics.
•For moderate disease (hypoxia, tachypnea, retractions, feeding difficulty), admit to hospital. Start low-flow oxygen; if fails, escalate to (HFNC) at 1 L/kg/min (max 20 L/min, FiO₂ to target SpO₂ ≥90%). HFNC reduces treatment failure compared to standard oxygen (RR 0.50, 95% CI 0.40-0.62) and lowers escalation to mechanical ventilation.
•For severe disease (persistent hypoxia, apnea, marked respiratory distress, inability to feed), admit to ICU. HFNC is preferred over bubble CPAP as initial noninvasive support (lower treatment failure 23.7% vs 42.4%; RR 0.56). If HFNC fails, consider CPAP at 5-8 cm H₂O; use helmet interface for better tolerance (failure due to intolerance 17% vs 54% with mask).
•Mechanical ventilation is reserved for severe respiratory failure, apnea, or impending respiratory failure. Use lung-protective strategies with PEEP 5-8 cm H₂O.
•Do not routinely use bronchodilators (albuterol, salbutamol, epinephrine), they do not improve oxygen saturation, reduce admission, or shorten length of stay (Cochrane meta-analysis of 30 trials, 1992 infants).
•Do not routinely use corticosteroids (systemic or inhaled), they are ineffective in reducing hospital admission or length of stay. In the ICU, the combination of systemic corticosteroids and inhaled epinephrine may reduce duration of positive pressure support (geometric mean 26 vs 40 hours; adjusted ratio 0.66), but this is not recommended outside intensive care.
•Do not use hypertonic saline nebulization, it does not reduce hospital admission (adjusted risk difference -3.2%) and causes more cough. In hospitalized infants, evidence is conflicting: Cochrane meta-analysis shows a modest reduction in LOS (MD -0.41 days), but reanalysis adjusting for heterogeneity found no effect.
•Do not use antibiotics unless there is proven bacterial co-infection, antibiotic overuse is common (34-99% of cases) despite no benefit.
•Do not use chest physiotherapy, chest percussion, or postural drainage, they have no effect on length of stay.
•Do not routinely use caffeine citrate for apnea, a single dose of 25 mg/kg does not reduce apnea episodes or need for ventilation.
•Antiviral therapy: (RSV fusion inhibitor) 10-40 mg twice daily for 5 days based on weight improved Wang score by day 3 (difference -0.8 points, p=0.002) in a phase 3 trial, but resistance-associated mutations emerged in 9% of recipients. It is not yet standard of care.
•Prevention: administer (single intramuscular dose) to all infants <8 months entering their first RSV season, real-world effectiveness ~74% reduction in RSV hospitalizations. For high-risk infants (e.g., congenital heart disease, chronic lung disease, preterm <29 weeks), palivizumab 15 mg/kg IM monthly during RSV season remains an option but is largely superseded by nirsevimab.
•Monitor serial clinical severity scores, heart rate, respiratory rate, SpO₂, and feeding ability. Escalate if: persistent tachypnea, SpO₂ <90% despite oxygen, worsening work of breathing, or apnea.
•Discharge criteria: stable SpO₂ ≥90% in room air, adequate oral feeding (≥75% of usual volume), no significant respiratory distress, and reliable caregiver support. Home oxygen therapy is a feasible alternative to prolonged hospitalization for selected infants, reducing hospital bed-days by nearly 2 days.
•Counsel families: cough may persist for 2-3 weeks; avoid smoke exposure; hand hygiene and breastfeeding are protective; return if signs of respiratory distress (grunting, nasal flaring, retractions, poor feeding, lethargy). Home pulse oximetry is not recommended as desaturations are common and do not predict unscheduled visits.

Board Review — High Yield

•First episode of wheezing in infant <2 years, key definition: recurrent wheezing is not bronchiolitis.
•RSV is the most common cause, responsible for 70-80% of hospitalized cases.
•Apnea can be the presenting sign in infants <2 months, even without wheezing.
•No routine testing, diagnosis is clinical; chest X-ray and viral testing are not recommended.
•HFNC reduces treatment failure, 1 L/kg/min initial flow; avoid >6 L/min due to air leak risk.
•Corticosteroids and bronchodilators are ineffective, do not use routinely.
•Nirsevimab prevents RSV hospitalization, single dose, 74% effectiveness.
•Most common complication is post-bronchiolitis wheezing, 1 in 5 hospitalized infants have subsequent respiratory admission by age 5.
•RDAI score, most validated severity score; use trend not single value.
•Maternal RSV vaccination emerging but not yet standard.

Deep Dive — Evidence Details

Definition, Classification & Nomenclature

▸Bronchiolitis is defined as the first episode of wheezing in infants <2 years, most commonly caused by RSV.
▸The diagnosis is clinical; recurrent wheezing episodes should be considered early asthma, not bronchiolitis.
▸While hospitalization rates have declined, resource use (mechanical ventilation, costs) continues to rise.

HY High Yield: The first episode of wheezing in an infant <2 years is bronchiolitis; recurrent wheezing is not, treat accordingly.

Bronchiolitis is inflammation of the small airways also known as the bronchioles in the lungs. Acute bronchiolitis is caused by a viral infection, usually affecting children younger than two years of age. Symptoms may in — Bronchiolitis — Bronchiolitis is inflammation of the small airways also known as the bronchioles in the lungs. Acute bronchiolitis is caused by a viral infection, usu...Wikipedia ↗

Bronchiolitis is an acute, viral-induced lower respiratory tract infection (LRTI) in infants <2 years of age, characterized by airway inflammation, mucus plugging, and bronchiolar obstruction, most commonly caused by (RSV).

Also Called / Synonyms

Acute viral bronchiolitis
RSV bronchiolitis
Wheezy bronchitis (historical)
Capillary bronchitis (rare)

Key Abbreviations

RSV: respiratory syncytial virus
HFNC: high-flow nasal cannula
LOS: length of stay
LRTI: lower respiratory tract infection

Clinical Definition and Boundaries

The diagnosis remains clinical, based on the first episode of wheezing or crackles in an infant <2 years, accompanied by rhinorrhea, cough, and tachypnea during the RSV season. The UK and US guidelines define bronchiolitis as the first episode of wheezing in children <2 years ^[21]^B2c. This distinction is critical: recurrent wheezing episodes in the same age group are more likely and should not be labeled bronchiolitis, as they carry different virologic (rhinovirus over RSV) and atopic risk factors ^[21]^B2c.

Classification of Clinical Phenotypes

Phenotype	Key Distinguishing Feature	Associated Marker/Subtype
First-episode bronchiolitis	No prior wheezing; peak age 2-10 weeks	RSV (70-80% of hospitalizations) ^[20]^B3b
Recurrent wheezing (post-bronchiolitis)	≥2 prior wheezing episodes; older infant	Rhinovirus, elevated IgE, eosinophilia ^[21]^B2c
Bronchiolitis obliterans (distinct entity)	Persistent airflow obstruction after severe insult	Post-HSCT, post-infectious (e.g., adenovirus) ^[8]^A1c

Clinical Significance

Bronchiolitis is the leading cause of hospitalization in US infants <1 year, accounting for over 149,000 admissions annually and $543 million in direct costs ^[6]^B2c. While hospitalization incidence declined from 17.9 to 13.5 per 1000 person-years between 2000 and 2016, the proportion of hospitalized children with complex chronic conditions rose 117% and mechanical ventilation use increased 184% ^[3]^B2c. The vast majority of cases (87%) are managed in primary care, yet hospital resource use continues to escalate ^[22]^B3b.

The clinical course typically follows a catarrhal phase (rhinorrhea, cough), then a respiratory distress phase (tachypnea, wheezing, hypoxemia) peaking at days 3-5, followed by gradual recovery. The pathophysiology underlying this age-dependent obstruction is detailed in the next section.

Pearl: Bronchiolitis is a first-episode wheezing illness in infants <2 years; applying this strict definition avoids conflating early asthma with viral bronchiolitis and prevents unnecessary bronchodilator and corticosteroid use.

Pathophysiology & Developmental Mechanism

▸RSV infects bronchial epithelial cells, causing epithelial necrosis, syncytial formation, and airway obstruction, with peak viral replication by day 4.
▸IL-6 elevation >200-fold above normal is a hallmark of the hyperinflammatory response that can precipitate rapid deterioration and brain edema.
▸ST2-mediated type 2 immunity (IL-13, periostin, arginase, NOS uncoupling) drives RSV-associated pulmonary hypertension, offering a potential therapeutic target.
▸Prenatal exposures (viruses, pollutants) can program aberrant airway innervation and smooth muscle contractility, increasing susceptibility to severe bronchiolitis and later asthma.

HY High Yield: IL-6 >200-fold above normal is a critical marker of cytokine storm in severe RSV bronchiolitis, even in infants with normal CRP [24].

! Warning: Previously healthy full-term infants can deteriorate within half a day of symptom onset due to a cytokine-driven process; do not be falsely reassured by absence of underlying risk factors [24].

Building on the definition, the pathogenesis of bronchiolitis centers on viral infection of the airway epithelium, but the severity and clinical course are shaped by developmental and immunologic factors unique to infancy. The following chain of events, from viral entry to systemic effects, explains why young infants, especially those born preterm, are vulnerable to severe disease.

Viral Pathogenesis and Epithelial Injury

Viral entry and replication. Respiratory syncytial virus (RSV) enters through the nasopharyngeal or conjunctival mucosa and, after an incubation period of 4-6 days, spreads to the lower respiratory tract ^[26]^C4. The virus shows predominant tropism for bronchial epithelial cells, sparing the alveoli in most cases ^[24]^C4. By day 4 after infection, viral replication is extensive in the bronchioles, as demonstrated in the lamb model, which closely mirrors human infant lung structure ^[29]^D5.
Epithelial damage and airway obstruction. RSV infection causes degeneration and necrosis of epithelial cells, syncytial cell formation, neutrophil infiltration, and epithelial hypertrophy and hyperplasia ^[29]^D5. Sloughed epithelium, inflammatory debris, and mucus plug the small airways, producing the classic wheeze and hyperinflation. In severe cases, airway obstruction leads to atelectasis and impaired gas exchange.

Host Immune Response and Cytokine Cascade

Cytokine storm. The immune response, rather than direct viral cytopathy, drives the most severe outcomes. In fatal cases, interleukin-6 (IL-6) levels rise more than 200-fold above normal despite a normal C-reactive protein, suggesting that IL-6 may reflect the extent of bronchial epithelial damage and contribute to brain edema ^[24]^C4. This cytokine surge can precipitate rapid deterioration, even in previously healthy full-term infants.
Type 2 immunity and pulmonary . RSV bronchiolitis can trigger pulmonary hypertension, especially in children with congenital heart disease. In a neonatal mouse model, RSV reinfection increased right ventricle systolic pressure, shortened pulmonary artery acceleration time, and decreased the acceleration time/ejection time ratio ^[28]^D5. These changes were associated with upregulation of periostin and IL-13, increased arginase bioactivity (arginase 1 and 2), and induction of nitric oxide synthase (NOS) uncoupling. The signaling pathway is mediated by suppression of tumorigenicity 2 (ST2); ST2 knockout prevented pulmonary hypertension by suppressing NOS uncoupling, identifying a potential therapeutic target ^[28]^D5.

Developmental Lung Susceptibility

Prenatal programming of airway reactivity. The infant lung is still maturing, and environmental exposures during critical developmental windows can permanently alter airway structure and function. Nanosized particles, including respiratory viruses, can cross the placenta and interfere with lung development, leading to aberrant cholinergic innervation, enhanced airway smooth muscle contractility, and impaired innate immunity that persist after birth ^[27]^D5. These changes may predispose to bronchiolitis severity and later asthma, even without atopic predisposition.
Preterm vulnerability. Preterm birth is a well-established risk factor for severe RSV bronchiolitis. In the lamb model, disease severity is greater in preterm lambs compared with full-term lambs, paralleling human infant data ^[29]^D5. The preterm lung has reduced surfactant, smaller airways, and an immature immune system, all of which amplify the effects of viral infection.

Extrapulmonary and Systemic Effects

Hematogenous spread and organ involvement. RSV can spread hematogenously to infect extrapulmonary tissues, including the brain and heart, causing encephalopathy, encephalitis, and cardiomyopathy ^[24]^C4^[26]^C4. Transplacental transmission from mother to fetus has also been documented, suggesting that RSV can affect lung development before birth ^[26]^C4^[27]^D5.
Genetic and atopic modifiers. Susceptibility to severe RSV infection is partly genetically determined. Atopic dermatitis is significantly associated with severe bronchiolitis (odds ratio 2.72, 95% CI 1.60-4.63), independent of known risk factors, though the mechanism remains unclear ^[25]^B2b. Genetic immune disorders predisposing children to severe infections are increasingly understood, and RSV bronchiolitis pathophysiology is now better characterized ^[30]^D5.

Key Mediator	Role in RSV Bronchiolitis	Source
IL-6	Elevated >200-fold; reflects epithelial damage; contributes to brain edema	^[24]^C4
IL-13, Periostin	Type 2 immunity; associated with pulmonary hypertension	^[28]^D5
Arginase 1 & 2	Increased bioactivity; NOS uncoupling	^[28]^D5
ST2	Signaling receptor; mediates NOS uncoupling and pulmonary hypertension	^[28]^D5

Pearl: The extreme IL-6 elevation (>200-fold) in sudden death cases suggests that cytokine storm, not direct viral cytopathy, drives the most severe outcomes; clinicians should maintain a high index of suspicion for rapid deterioration in previously healthy infants.

Epidemiology, Etiology & Risk Factors

▸Bronchiolitis hospitalization incidence declined from 17.9 to 13.5 per 1000 person-years in the US (2000-2016), but mechanical ventilation use and costs increased substantially [3].
▸Down syndrome is an independent risk factor for severe RSV bronchiolitis, even in term infants without congenital heart disease [35].

HY High Yield: Severe RSV bronchiolitis often occurs in healthy full-term infants under 3 months; do not rely solely on comorbidity-based risk stratification [57].

From the pathophysiologic mechanisms of airway inflammation and obstruction, the clinical burden of bronchiolitis emerges with a well-defined epidemiologic profile. The condition is the most common lower respiratory tract infection in infants under 2 years, with respiratory syncytial virus (RSV) accounting for the majority of cases ^[31]^A1c^[51]^B2a.

Incidence and Prevalence

In the United States, the incidence of bronchiolitis hospitalization among children <2 years declined from 17.9 to 13.5 per 1000 person-years between 2000 and 2016 (25% decrease; P trend < .001) ^[3]^B2c. In England, the 2011 admission rate was 46.1 per 1000 infants <1 year, with rates rising 1.8% annually from 2004 to 2011 ^[15]^B2c. Globally, RSV is detected in 21.6% of children with respiratory tract infections, with the highest prevalence in infants <6 months (33.8%) and in those with bronchiolitis (56.9%) ^[51]^B2a. Human metapneumovirus (HMPV) is identified in 4.56% of Chinese children with respiratory infections, with bronchiolitis showing the highest rate (14.11%) ^[52]^B2a.

Demographic and Geographic Distribution

Bronchiolitis disproportionately affects males, infants from low-income households, and those living in disadvantaged neighborhoods ^[48]^B2b^[50]^B2b. In a Swedish nationwide cohort, severe RSV outcomes (ICU admission or death) occurred at a median age of ****, and of these infants had no underlying comorbidity ^[57]^B2b. Black children in the US have higher odds of respiratory impairment following severe bronchiolitis (aOR 7.59) when using race-neutral spirometry equations ^[47]^B2b. Geographic variation is marked: a fivefold difference in admission rates exists across English local authorities ^[15]^B2c, and HMPV detection is highest in Northeast China (10.84%) and Southwest China (10.16%) ^[52]^B2a.

Temporal Trends

Hospitalization rates for bronchiolitis have decreased overall, but the proportion of children with complex chronic conditions increased from 6% to 13% (117% increase), and mechanical ventilation use rose from 2% to 5% (184% increase) from 2000 to 2016 ^[3]^B2c. Hospital costs rose from $449 million to $734 million (63% increase) ^[3]^B2c. In Finland, the epidemic pattern shifted from a biannual to an annual cycle, with peak incidence moving from December-February to February-April ^[42]^B2b. The pandemic disrupted RSV seasonality dramatically: a marked decrease in bronchiolitis diagnoses occurred in 2020-2021, followed by atypical summer peaks in subsequent years ^[53]^C4^[59]^B2b.

Risk Factors

Multiple perinatal, genetic, and social factors increase the risk of severe bronchiolitis. The strongest associations are summarized in the table below.

Risk Factor	Odds Ratio / Hazard Ratio (95% CI)	Evidence Level
Comorbidities (any)	OR 5.33 (2.82-10.10) ^[48]^B2b	2b
Siblings aged 0-3 years	aHR 2.92 (2.57-3.31) ^[57]^B2b	2b
(term, no CHD)	7.6% vs 0.7% hospitalized ^[35]^B2b	2b
Neighborhood deprivation (most vs least)	OR 2.2 (1.5-3.6) ^[50]^B2b	2b
Low income	OR 1.53 (1.01-2.34) ^[48]^B2b	2b
Young maternal age	Increased risk ^[15]^B2c	2c
Maternal smoking	Increased risk ^[15]^B2c	2c
Low birth weight	Increased risk ^[15]^B2c	2c
Age <1.5 months	aOR not reported, but significant ^[58]^B2b	2b
Cardiovascular disease	aOR not reported, but significant ^[58]^B2b	2b
Congenital/genetic disease	aOR not reported, but significant ^[58]^B2b	2b
Ozone exposure (males)	HR 1.168 (1.020-1.336) ^[54]^B2b	2b

Seasonal Variation

RSV bronchiolitis follows a predictable winter epidemic in temperate climates, typically peaking between December and February ^[42]^B2b. In recent years, the peak has shifted later into spring in some regions ^[42]^B2b. HMPV shows spring and winter peaks ^[52]^B2a. The COVID-19 pandemic caused profound disruption, with RSV virtually disappearing during the 2020-2021 winter and re-emerging in atypical summer months ^[53]^C4^[59]^B2b.

Special Considerations

Down syndrome: An independent risk factor for severe RSV lower respiratory tract infection, even in term infants without congenital heart disease (7.6% hospitalized vs 0.7% controls) ^[35]^B2b.
Very preterm infants with BPD: Living in a disadvantaged neighborhood increases respiratory rehospitalization risk nearly threefold (aIRR 2.79) ^[49]^B2b.
Post-infection sequelae: Infants hospitalized for bronchiolitis have a threefold to fivefold increased risk of subsequent respiratory admissions for asthma (HR 4.35) and wheezing (HR 5.02) by age 5 years ^[39]^B2b.
Prevention impact: Nirsevimab immunization (87.5% coverage) reduced RSV positivity from 47.9% to 32.4% and halved absolute bronchiolitis admissions in one Italian center ^[55]^B2b.

Pearl: Severe RSV bronchiolitis often strikes healthy full-term infants under 3 months of age; risk stratification should include not only comorbidities but also social and perinatal factors like young siblings, multiple birth, and neighborhood deprivation ^[57]^B2b^[48]^B2b.

Clinical Presentation

▸Clinical course progresses from coryza to lower respiratory signs over 1-2 days, with nadir at 2-5 days; age <2 months, HR >160/min, and SpO₂ <87% are independent predictors of ICU admission [61].
▸Apnea may be the sole presenting sign in young infants, especially those <2 months, and warrants immediate evaluation for bronchiolitis even without wheeze [69].
▸Atypical presentations (persistent wheeze in older toddlers, failure to thrive, recurrent severe disease) should prompt consideration of alternative diagnoses such as asthma, foreign body, or interstitial lung disease [63,75].

HY High Yield: In an infant <2 months with apnea, think bronchiolitis first. Apnea can precede respiratory distress by 6-12 hours and is a stronger predictor of ICU admission than wheeze.

! Warning: SpO₂ <87% at presentation predicts ICU admission (OR 2.2, 95%) [61]. Do not delay escalation if this threshold is met.

From the epidemiologic patterns above, the clinical presentation of bronchiolitis follows a predictable but age-dependent course. The illness typically begins with coryzal symptoms (rhinorrhea, cough, low-grade fever) that evolve over 1-2 days into lower respiratory signs: tachypnea, wheezing, and increased work of breathing. The nadir of respiratory distress occurs at 2-5 days after symptom onset, after which gradual improvement is expected over 1-2 weeks. Severe cases may progress more rapidly, time of onset ≤2 days to hospital presentation is an independent predictor of ICU admission (OR 0.78, 95% CI 0.65-0.94) ^[61]^B2b.

Presenting Symptoms

Cough is the most universal symptom, present in >80% of cases ^[66]^B2b. Parents report a “tight” or “rattly” cough, often worse at night. Rhinorrhea and fever are common but not universal; temperature >38°C occurs in roughly half of hospitalized infants. Feeding difficulty, due to nasal congestion, tachypnea, and respiratory fatigue, is a frequent reason for admission. Older infants (≥12 months) may localize chest discomfort, whereas younger infants (<2 months) often present with apnea, lethargy, or poor feeding rather than prominent cough ^[69]^D5. The combination of age <2 months, heart rate >160/min, and SpO₂ <87% at presentation identifies infants at highest risk for ICU admission (OR 1.8, 1.2, and 2.2 respectively) ^[61]^B2b.

Physical Examination Findings

Vital signs are the first clue. Tachypnea (respiratory rate >50-60/min) is nearly universal in moderate disease. Hypoxemia, defined as SpO₂ <90% in most guidelines, but <87% in the ED predicts ICU admission ^[61]^B2b, warrants supplemental oxygen. Auscultation reveals diffuse crackles (crepitations) and expiratory wheezes; in severe disease, breath sounds may be diminished due to air trapping. The chest is often hyperinflated, and subcostal, intercostal, or suprasternal retractions signify increased work of breathing. Nasal flaring and bobbing are signs of imminent respiratory failure. In the youngest infants, apnea (≥20 seconds) may be the sole presenting sign, even without significant wheeze ^[69]^D5.

Phenotypic Variants

Variant	Key Features	Frequency
RSV bronchiolitis	Classic winter peak; severe in infants <3 months; wheeze + crackles; longer oxygen requirement ^[71]^B2b	~60% of hospitalized cases
Adenovirus bronchiolitis	High fever, prolonged cough; may cause pneumonia; risk of severe disease in immunocompromised ^[60]^C4^[80]^C4	~6% of bronchiolitis
SARS-CoV-2 bronchiolitis	Mild course; rarely requires oxygen; peak age similar to RSV; notable absence of fever in some ^[53]^C4	<3% of bronchiolitis (2020-2021)

Red Flags

Immediate signs of severe disease that should trigger escalation include: apnea, severe hypoxemia (SpO₂ <87%), persistent tachycardia (HR >160), inability to feed or maintain hydration, lethargy, and signs of respiratory failure (grunting, head bobbing, severe retractions, or rising pCO₂ on blood gas). Infants with comorbidities (prematurity, congenital heart disease, chronic lung disease) are at 5-fold higher odds of critical care admission or death after ED discharge (OR 5.33) ^[48]^B2b.

Atypical Presentations

Bronchiolitis can mimic other conditions. A first-time wheeze in a 2-year-old should raise suspicion for asthma or ^[63]^C4. Infants with persistent crackles, failure to thrive, and clubbing may have an such as surfactant protein C mutations ^[75]^C4. Recurrent or severe bronchiolitis in an older child warrants evaluation for immune deficiency, cystic fibrosis, or ciliary dyskinesia. In the post- era, SARS-CoV-2 bronchiolitis is rare and mild, but RSV and rhinovirus remain the dominant pathogens ^[53]^C4^[81]^B2b.

Pearl: In an infant <2 months with apneic episodes but minimal wheezing, always consider bronchiolitis, apnea can precede respiratory distress by 6-12 hours and is a stronger predictor of ICU admission than auscultatory findings ^[61]^B2b^[69]^D5.

Diagnosis & Workup

▸Bronchiolitis is a purely clinical diagnosis; no laboratory or imaging test is required for typical cases.

Dx Diagnostic Essentials: **Gold-standard test:** Clinical diagnosis. No confirmatory test is required for typical bronchiolitis in infants 1-23 months with coryzal prodrome, tachypnea, and crackles/wheeze.

HY High Yield: **Test-order pitfall:** Chest radiography is not recommended in typical bronchiolitis; it increases antibiotic prescriptions without improving outcomes. Overuse is highest in non-pediatric emergency departments and rural settings.

From the clinical presentation of coryza, cough, and tachypnea in an infant, the diagnosis of bronchiolitis is made at the bedside, no laboratory or imaging test is required for confirmation in typical cases. The gold-standard diagnostic test for bronchiolitis is a clinical diagnosis based on history and physical examination, supported by the characteristic age range (1-23 months) and a consistent viral prodrome ^[83]^A1c.

History and Physical

Key historical elements include the onset of upper respiratory symptoms (rhinorrhea, nasal congestion, cough) followed by progressive lower respiratory signs (tachypnea, retractions, wheezing, crackles) over 2-5 days. Ask about fever, feeding intolerance, decreased urine output, and apnea (especially in infants <2 months). Red flags that upgrade urgency include: apnea, cyanosis, severe respiratory distress (grunting, bobbing, nasal flaring), oxygen saturation <90% on room air, and inability to feed ^[83]^A1c. On auscultation, crackles (rales) are often heard; wheezing is common but not required for diagnosis. The presence of both crackles and wheeze in a febrile infant <12 months is highly suggestive of bronchiolitis.

Gold-Standard Test

The gold standard is the clinical diagnosis. In a 2014 AAP guideline, diagnosis rests on the presence of acute-onset lower respiratory illness with coryzal prodrome, tachypnea, and crackles/wheeze in a child ≤23 months ^[83]^A1c. No confirmatory test is needed for . The AAP recommends against routine chest radiography, viral testing, and complete blood counts in typical bronchiolitis ^[83]^A1c.

Diagnostic Testing

Routine testing is not recommended. A systematic overview of 59 studies (N=23,605 infants) found that chest radiography, laboratory tests, and viral testing have very low certainty evidence for clinical utility in typical bronchiolitis; chest radiography increased antibiotic prescriptions without improving outcomes ^[101]^B2a. In a multicenter cohort, hospitals with clinical practice guidelines had uniform recommendations against routine tests, but actual ordering only decreased with prolonged guideline implementation and online accessibility ^[85]^B2b.

When should testing be considered?

Chest radiography only if the diagnosis is uncertain (e.g., suspected foreign body, pneumonia, or atelectasis) or in severe disease requiring ICU admission. Despite this, overuse persists: in one study, 18% of children with bronchiolitis received a chest radiograph ^[4]^B2c. Quality improvement initiatives using high-reliability workflow redesign reduced CXR use from 42% to 19% ^[88]^C4.
Viral testing (e.g., RSV PCR) does not alter management or outcomes in typical cases and is not routinely indicated ^[83]^A1c. It may be useful for cohorting hospitalized infants to prevent nosocomial spread, but this is a public health decision, not a clinical one.
Urinalysis and urine culture are not routinely needed. The prevalence of concomitant UTI in bronchiolitis is 3.1% (95% CI, 1.8%-4.6%) using heterogeneous definitions ^[1]^A1a. When a positive urinalysis (pyuria or nitrites) is added as a diagnostic criterion, the prevalence drops to 0.8% (95% CI, 0.3%-1.4%), below recommended testing thresholds ^[1]^A1a.
Blood cultures, CBC, and inflammatory markers are not recommended. In a cohort of 276 infants with severe RSV bronchiolitis in PICUs, only 13.4% had a bacterial pathogen isolated, yet 82.6% received ^[82]^C4. Procalcitonin and CRP may have some benefit in predicting bacterial co-infection in ICU patients, but evidence is very low certainty ^[101]^B2a.

Imaging

Chest radiography is not recommended for routine diagnosis. It has insufficient diagnostic accuracy in bronchiolitis, does not change management, and is associated with increased antibiotic use ^[101]^B2a. The AAP advises against its use unless the child has an atypical presentation (e.g., focal signs, persistent fever, or severe disease) ^[83]^A1c.

Differential Diagnosis

When the presentation is not classic, consider:

Condition	Key Distinguishing Features
Asthma (first episode)	Often older (>12 months), recurrent wheezing episodes, family history of atopy, triggers.
	Sudden onset of choking/coughing, unilateral wheeze or decreased breath sounds, history of small object exposure.
Pneumonia	Focal crackles, high fever, dullness to percussion; chest radiograph shows consolidation.
	Paroxysmal cough with inspiratory whoop, post-tussive emesis, apnea, absence of fever; PCR confirmatory.
Congenital heart disease	Cyanosis, murmur, hepatomegaly, poor feeding; echocardiogram diagnostic.
Human metapneumovirus, adenovirus, bocavirus	Clinically indistinguishable; viral testing may identify co-infections but does not change management.

Pertussis is an uncommon cause of bronchiolitis-like illness in hospitalized infants (<0.5%) ^[23]^B2b. Human bocavirus is frequently detected in children with recurrent wheezing and bronchiolitis, but as a single pathogen it is less common than RSV ^[121]^B2b.

Prediction Models for Admission and Severity

Several clinical prediction rules exist to aid decision-making, but none are routinely used in all settings. The bronchiolitis risk of admission score (BRAS) incorporates age, respiratory rate, heart rate, oxygen saturation, and duration of symptoms, with an area under the ROC curve of 0.81 (95% CI 0.77-0.85) at the optimal cut-off ^[108]^B2b. A machine learning model using three admission variables (age, retractions, oxygen saturation) showed good predictive performance (Kendall's tau 0.654, p<0.001) for severity classification ^[109]^B3b. These tools are not yet validated for widespread use but suggest that a simplified clinical assessment may be sufficient for triage.

Pearl: In a well-appearing infant with classic signs, the diagnosis of bronchiolitis is clinical, no test is needed. Overuse of chest radiography and antibiotics remains common, especially in emergency and rural settings; the single best intervention is to follow the dictum: "diagnose, support, observe."

Differential Diagnosis of Bronchiolitis

Condition	Key Distinguishing Features
Asthma (first episode)	Often older (>12 months), recurrent wheezing, family history of atopy, triggers.
Foreign body aspiration	Sudden onset of choking/coughing, unilateral wheeze or decreased breath sounds, history of small object exposure.
Pneumonia	Focal crackles, high fever, dullness to percussion; chest radiograph shows consolidation.
Pertussis	Paroxysmal cough with inspiratory whoop, post-tussive emesis, apnea, absence of fever; PCR confirmatory.
Congenital heart disease	Cyanosis, murmur, hepatomegaly, poor feeding; echocardiogram diagnostic.
Human metapneumovirus, adenovirus, bocavirus	Clinically indistinguishable; viral testing may identify co-infections but does not change management.

Severity Grading, Staging & Risk Stratification

▸The RDAI (0-17) is the most validated bronchiolitis severity score, with good interrater reliability (ICC 0.93) but substantial test-retest error.
▸Risk stratification scores such as RISC-Malawi (MUAC) predict mortality with AUROC 0.83 in low-resource settings, outperforming other ALRI scores.
▸No single score is sufficient; combine clinical assessment with a validated tool to guide monitoring intensity and disposition.

HY High Yield: The Wang score (0-12) was the primary endpoint in the only positive phase 3 drug trial for bronchiolitis (ziresovir); a baseline score ≥8 identifies a higher-risk subgroup.

Dx Diagnostic Essentials: RDAI test-retest error spans nearly 8 points, always corroborate the score with oxygen saturation, feeding ability, and clinical trajectory.

Once the diagnosis is confirmed, the clinician's next task is to assign a severity grade, a step that determines the need for supplemental oxygen, disposition to the ward versus the intensive care unit, and the intensity of monitoring. Several validated scores translate clinical findings into reproducible risk tiers, though no single tool has achieved universal adoption.

Clinical Severity Scores

The Respiratory Distress Assessment Instrument (RDAI) remains the most extensively studied bronchiolitis severity score. It assigns points for retractions, wheezing, and respiratory rate (range 0-17). Interrater reliability is good (intraclass correlation coefficient 0.93), but test-retest measurement error is considerable (limits of agreement -3.80 to 3.64, ~20% of the scale range) ^[124]^C4. Construct validity is poor to moderate: baseline RDAI correlates weakly with respiratory rate (r = 0.38) and higher scores are associated with hospital admission (odds ratio 1.36 per point) ^[124]^C4. The Wang bronchiolitis clinical score (0-12) incorporates respiratory rate, retractions, accessory muscle use, and auscultation; it was the primary endpoint in the ziresovir phase 3 trial, where a baseline score ≥8 identified a higher-risk subgroup ^[34]^A1b. The modified Woods clinical asthma score (0-10) is used in some pediatric intensive care settings, though its correlation with inspiratory demand is not significant ^[131]^C4. All three scores are moderately responsive to clinical change, but none captures all determinants of severity (e.g., feeding intolerance, oxygen saturation) ^[124]^C4.

Score	Components	Range	Key Strengths	Limitations
RDAI	Retractions, wheezing, respiratory rate	0-17	Most validated; good interrater reliability ^[124]^C4	High test-retest error; poor construct validity ^[124]^C4
Wang	Respiratory rate, retractions, accessory muscles, auscultation	0-12	Used in phase 3 RCT; responsive to treatment ^[34]^A1b	Limited published validity data
Modified Woods	Respiratory rate, retractions, auscultation, cyanosis, mental status	0-10	Common in PICU ^[131]^C4	Not specifically validated for bronchiolitis

Risk Stratification for Severe Outcomes

Beyond clinical scores, several prediction models estimate the risk of in-hospital mortality or intensive care need. The RISC-Malawi (MUAC) score, originally developed for pneumonia, showed the highest discrimination for mortality (AUROC 0.83) in a Kenyan cohort of 2182 children with severe acute lower respiratory infections, outperforming the RISC (HIV-negative), mRISC, PERCH, PREPARE, and ReSVinet scores ^[132]^B2b. Adding nutritional status (mid-upper arm circumference) to the ReSVinet score improved its AUROC from 0.72 to 0.79 ^[132]^B2b. A separate prediction model for septic shock in RSV bronchiolitis, developed in 224 Chinese PICU patients, identified four independent predictors: fungal co-infection (aOR 9.01), elevated admission glucose (aOR 1.23), decreased antithrombin III (aOR 0.96), and elevated interleukin-6 (aOR 1.00), yielding an AUC of 0.89 ^[68]^B2b. These models require external validation before widespread clinical use.

Integrating Scores into Decision-Making

In practice, severity is commonly triaged by oxygen saturation (<90% indicates severe disease), respiratory rate, and work of breathing. The AAP expert panel recommends intermittent vital sign monitoring for mild-to-moderate bronchiolitis and continuous monitoring only for severe disease ^[123]^D5. A structured score such as the RDAI can objectify the initial assessment and track response to therapy, but clinicians should remain aware of its measurement error. Combining a clinical score with a risk prediction tool (e.g., RISC-Malawi in settings with high mortality) may refine disposition decisions, particularly in resource-limited environments ^[132]^B2b.

Pearl: The RDAI is the best-studied bronchiolitis severity score, but its ±4-point measurement error means a single value should never supplant clinical judgment; use the trend over 4-6 hours, not the absolute number, to guide escalation.

Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization

▸First-line management is supportive: oxygen, nasal suctioning, and hydration; no medication is routinely recommended.
▸High-flow nasal cannula (HFNC) is preferred over bubble CPAP for initial noninvasive respiratory support, with lower treatment failure and escalation rates.
▸In the ICU, systemic corticosteroids plus inhaled epinephrine may reduce duration of positive‑pressure support, but this should not be used in the emergency department or ward.

! Warning: **Do not** use hypertonic saline, bronchodilators, or corticosteroids routinely in the emergency department or ward. In the ICU, the combination of systemic corticosteroids and inhaled epinephrine may be considered for severe disease [86].

Once severity is graded (see prior section), proceeds along two parallel pathways: a gestational-age- and physiology-based approach for neonates (especially those with transitional physiology) and a weight-based, PALS-style stabilization for older infants. The overarching goal is to provide respiratory support while avoiding interventions that lack evidence.

Step 1: Initial Assessment, Disposition, and Trigger for Escalation

All infants with bronchiolitis should receive immediate nasal and, if hypoxemic, supplemental oxygen to maintain SpO₂ ≥ 90%. The decision to admit hinges on the severity grade: mild disease (no hypoxia, mild respiratory distress) can be managed at home with careful parental education; moderate disease (hypoxia, tachypnea, retractions, feeding difficulty) warrants hospital admission; severe disease (persistent hypoxia, apnea, marked respiratory distress, inability to feed) mandates intensive care. The 2006 AAP guideline emphasizes that is the most objective tool for triage ^[31]^A1c (1c).

Step 2: First-Line Supportive Care, Oxygen, Hydration, and Nasal Suctioning

Oxygen therapy is the cornerstone. Low-flow nasal cannula (≤2 L/min) is first-line for mild hypoxia. In a randomized trial, high-flow warm humidified oxygen (HFWHO) delivered at up to 1 L/kg/min (max 20 L/min) did not shorten time to weaning compared with standard low-flow oxygen (median 20 h vs 24 h; HR 0.9) but did reduce treatment failure (14% vs 33%) ^[150]^A1b (1b). Enhanced nasal suctioning (battery-operated device) may reduce additional resource use compared with bulb suctioning (37.0% vs 26.2%; absolute risk difference 0.11, 95% CI 0.01-0.20; p = 0.03) but does not significantly reduce unscheduled revisits ^[159]^A1b (1b). Hydration should be provided enterally if the infant can feed safely; otherwise, intravenous fluids (isotonic) are indicated. Do not use chest physiotherapy, which has no effect on length of stay ^[31]^A1c (1c).

Step 3: Respiratory Support Escalation, High-Flow Nasal Cannula vs. Continuous Positive Airway Pressure

For infants with moderate to severe bronchiolitis who fail low-flow oxygen, high-flow nasal cannula (HFNC) is the preferred initial noninvasive support. In a randomized controlled trial of 118 children aged 1-23 months, HFNC had a lower treatment failure rate than nasal‑prong bubble CPAP (23.7% vs 42.4%; RR 0.56, 95%; p = 0.031) and a lower risk of escalation to mechanical ventilation (15.3% vs 39%; RR 0.39, 95%; p = 0.004). However, HFNC was associated with longer duration of oxygen therapy (4 vs 3 days) and hospital stay (6 vs 5 days) ^[158]^A1b (1b). When CPAP is chosen, the helmet interface is better tolerated than a facial mask (treatment failure due to intolerance 17% vs 54%) and requires less sedation (35% vs 100%) ^[145]^A1b (1b).

Step 4: Pharmacotherapy, What Works and What Does Not

No medication is routinely recommended for bronchiolitis. The 2006 AAP guideline and the 2023 Finnish guidelines (moderate evidence) state that corticosteroids, inhaled bronchodilators, and hypertonic saline should not be used routinely ^[31]^A1c (1c); ^[155]^A1c (1c). Specific evidence:

Antiviral therapy: Ziresovir, a novel RSV fusion inhibitor (10-40 mg twice daily for 5 days based on weight), improved the Wang bronchiolitis clinical score by day 3 (difference -0.8 points, 95% CI -1.3 to -0.3; p = 0.002) in a phase 3 trial ^[34]^A1b (1b). It is not yet widely available, and resistance‑associated mutations were detected in 9% of treated infants.
Palivizumab: A single intravenous dose of 15 mg/kg in infants ≤3 months old with RSV bronchiolitis did not reduce readmission (11% vs 9.3%; p = 0.51) or time to discharge ^[144]^A1b (1b). Do not use for treatment.

Step 5: Monitoring, Disposition, and De-escalation

Frequent reassessment of respiratory rate, SpO₂, work of breathing, and feeding ability is essential. Once the infant maintains SpO₂ ≥ 90% in room air, is feeding adequately, and has no significant respiratory distress, they can be considered for discharge. Home oxygen therapy is a feasible alternative to prolonged hospitalization in selected children, reducing time in hospital bed by nearly 2 days (55 h vs 97 h; p = 0.001) ^[153]^A1b (1b).

Respiratory Support Modality	Indication	Dose / Settings	Key Evidence	Evidence Level
Low‑flow nasal cannula	Mild hypoxia	≤2 L/min, FiO₂ to target SpO₂ ≥ 90%	Standard of care ^[31]^A1c	1c
High‑flow nasal cannula (HFNC)	Moderate to severe failure on low flow	1 L/kg/min (max 20 L/min), FiO₂ ≤ 0.6	Reduced treatment failure vs CPAP (RR 0.56) ^[158]^A1b	1b
Bubble CPAP (nasal prong)	Moderate to severe (failed HFNC)	5-8 cm H₂O	Higher failure vs HFNC ^[158]^A1b	1b
Helmet CPAP	Alternative to mask CPAP for intolerance	5-8 cm H₂O	Better tolerance, less sedation ^[145]^A1b	1b
Mechanical ventilation	Severe failure, apnea, impending respiratory failure	Volume‑ or pressure‑controlled, PEEP 5-8	Rescue therapy (no RCT data)	5

What NOT to Do

Do not routinely use bronchodilators (albuterol, epinephrine) or corticosteroids outside the ICU setting ^[31]^A1c ^[155]^A1c.
Do not use hypertonic saline nebulization (no consistent benefit, more adverse events) ^[143]^A1b ^[147]^A1b ^[148]^A1b.
Do not use unless there is proven bacterial co‑infection ^[31]^A1c.
Do not use chest physiotherapy ^[31]^A1c.

Pearl: For infants with moderate to severe bronchiolitis, early HFNC reduces treatment failure and escalation to mechanical ventilation compared with bubble CPAP; pharmacotherapy has no role in the emergency department or ward, but the combination of systemic corticosteroids and inhaled epinephrine may shorten positive‑pressure support in the ICU ^[86]^A1b ^[158]^A1b.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength of disagreement	Implication for practice
Role of hypertonic saline	AAP 2006 - does not recommend routine use ^[31]^A1c	Some early RCTs - found reduced LOS ^[152]^A1b	Strong (inconsistent evidence)	HS is not recommended; current best evidence shows no benefit ^[143]^A1b ^[147]^A1b
Use of epinephrine + corticosteroids in ED	Plint 2009 - unadjusted benefit became insignificant after adjustment ^[149]^A1b	Gelbart 2022 - benefit in ICU (reduced pressure support duration) ^[86]^A1b	Moderate (different settings)	In ED, do not use routinely; in PICU, may be considered

Long-term & Definitive Management

▸Supportive care, oxygen with a target SpO2 ≥90%, remains the cornerstone; intermittent pulse oximetry is safe in nonhypoxemic infants.
▸High-flow nasal cannula at 1-2 L/kg/min reduces treatment failure compared with standard oxygen therapy; CPAP is reserved for hypercapnia or failure of HFNC.
▸Bronchodilators, corticosteroids, antibiotics, hypertonic saline, and chest physiotherapy do not improve clinical outcomes and are not recommended.

HY High Yield: **High-yield:** The only interventions that reduce treatment failure in bronchiolitis are oxygen supplementation and high-flow nasal cannula. Pharmacologic therapies (bronchodilators, corticosteroids, hypertonic saline) do not have a consistent evidence base and are not recommended by the AAP 2014 guideline.

! Warning: **Warning:** Do not use bronchodilators, corticosteroids, or antibiotics for routine bronchiolitis management. These are low-value interventions that increase cost and potential side effects without improving outcomes. Antibiotics only if concomitant bacterial infection is confirmed.

Once the infant is stabilized, ongoing focuses on respiratory support, avoidance of unnecessary interventions, and monitoring for clinical deterioration. The evidence base for definitive therapy is built on supportive care, with a growing role for targeted respiratory support and emerging antiviral therapy.

Step 1: Oxygen Therapy and Saturation Targets

Supplementary oxygen is the mainstay for infants with hypoxemia (SpO2 < 90%). The Bronchiolitis of Infancy Discharge Study (BIDS) demonstrated that targeting an oxygen saturation of ≥90% is equivalent to a target of ≥94% for time to resolution of cough (median 15.0 days in both groups) and is safe, with no significant difference in serious adverse events or readmission rates ^[168]^A1b (1b). The AAP 2014 guideline recommends this permissive threshold ^[83]^A1c (1c). In nonhypoxemic infants (SpO2 ≥90% and clinically improving), intermittent monitoring does not prolong hospital stay compared with continuous monitoring (mean length of stay 46.2 vs 48.9 hours, P = 0.77) and can be routinely used ^[165]^A1b (1b).

Step 2: Respiratory Support

High-flow nasal cannula (HFNC) reduces the need for escalation of care in infants with moderate-to-severe bronchiolitis. In the landmark multicentre RCT by Franklin et al., 12% of infants receiving HFNC required escalation of care versus 23% receiving standard oxygen therapy (risk difference -11 percentage points; 95% CI -15 to -7; P < 0.001) ^[166]^A1b (1b). The Cochrane review of 16 RCTs (2813 participants) confirmed that HFNC reduces treatment failure compared with standard oxygen therapy (RR 0.50, 95% CI 0.40 to 0.62) ^[17]^A1a (1a). Optimal flow rates are debated; a recent RCT found that 1 L/kg/min provided the best clinical improvement with fewer adverse events, while 2 L/kg/min had the lowest PICU admission rate (13.3%) and 3 L/kg/min was associated with higher complications (26.7%) and longer hospital stay ^[179]^A1b (1b).

Continuous positive airway pressure (CPAP) is indicated for infants with hypercapnia or severe respiratory distress who fail HFNC. A small RCT showed that nasal CPAP reduced PCO2 by 0.92 kPa after 12 hours compared with a rise of 0.04 kPa on standard therapy (P < 0.015) ^[175]^A1b (1b). When compared with HFNC, bubble CPAP (b-CPAP) was associated with a higher treatment failure rate within 24 hours (42.4% vs 23.7%; RR 0.56) and a higher need for noninvasive ventilation (39% vs 15.3%) ^[158]^A1b (1b). The helmet interface for CPAP is better tolerated than facial mask, with lower treatment failure due to intolerance (17% vs 54%) and less need for sedation (35% vs 100%) ^[145]^A1b (1b).

Step 3: Pharmacologic Adjuncts

Bronchodilators (albuterol, salbutamol) do not improve oxygen saturation, reduce hospital admission, or shorten length of stay. The Cochrane meta-analysis of 30 trials (1992 infants) found no benefit in oxygen saturation (MD -0.43, 95% CI -0.92 to 0.06) or hospital stay (MD 0.06 days, 95% CI -0.27 to 0.39) ^[182]^A1a (1a). The AAP 2014 guideline recommends against routine use of bronchodilators ^[83]^A1c (1c).

Corticosteroids (systemic or inhaled) are ineffective. The Cochrane meta-analysis of 17 trials (2596 participants) showed no reduction in hospital admission (RR 0.86, 95% CI 0.7 to 1.06) or length of stay (MD -0.18 days, 95% CI -0.39 to 0.04) ^[185]^A1a (1a). Combined therapy with nebulized epinephrine and oral in the emergency department reduced hospital admission by day 7 from 26.4% to 17.1% (RR 0.65, 95% CI 0.44 to 0.95; NNT = 11) in the unadjusted analysis, but this was not significant after adjustment for multiple comparisons ^[149]^A1b (1b). In the intensive care setting, the combination of systemic corticosteroids and inhaled epinephrine reduced the duration of positive pressure support (geometric mean 26 vs 40 hours; adjusted ratio 0.66, 95% CI 0.51-0.84) ^[86]^A1b (1b). Despite this, the AAP does not recommend routine use of corticosteroids ^[83]^A1c (1c).

Hypertonic saline (HS) has conflicting evidence. In the emergency department, 3% HS does not reduce hospital admission rates (adjusted risk difference -3.2%, 95% CI -8.7% to 2.2%) and causes more cough (8.9% vs 3.9%) ^[147]^A1b (1b). A separate ED trial showed less improvement in respiratory distress with HS than with normal saline ^[148]^A1b (1b). In hospitalized infants, the Cochrane meta-analysis reported a statistically significant but clinically modest reduction in length of stay (MD -0.41 days, 95% CI -0.75 to -0.07) ^[18]^A1a (1a), but a reanalysis that adjusted for heterogeneity and outlier populations found no effect (MD -0.21 days, 95% CI -0.43 to +0.02) ^[2]^B2b (2b). The AAP 2014 guideline does not recommend routine use of HS ^[83]^A1c (1c).

Epinephrine alone or with salbutamol does not improve outcomes. The network meta-analysis of 150 RCTs found that nebulized epinephrine reduced admission on day 1 (OR 0.64, 95% CI 0.44 to 0.93, low confidence) but not by day 7 ^[164]^A1a (1a). In hospitalized infants, racemic adrenaline was no more effective than saline ^[167]^A1b (1b).

Antivirals: Ziresovir, an RSV fusion inhibitor, showed promise in a phase 3 trial. The Wang bronchiolitis clinical score improved by -3.4 points vs -2.7 points with placebo (difference -0.8 points, 95% CI -1.3 to -0.3; P = 0.002) in hospitalized infants aged 1-24 months, and RSV viral load was reduced (-2.5 vs -1.9 log10 copies/mL) ^[34]^A1b (1b). Resistance-associated mutations emerged in 9% of recipients. Ziresovir is not yet standard of care.

Treatments without benefit: does not improve length of stay or oxygen requirement ^[172]^A1b (1b). Montelukast reduces eosinophil degranulation and recurrent wheezing episodes post-RSV ^[171]^A1b (1b), but is not indicated for acute management. Caffeine citrate does not reduce apnea episodes in bronchiolitis ^[151]^A1b (1b). Topical nasal phenylephrine, chest physiotherapy (prolonged slow expiration technique), and heliox (except via tight-fitting mask/CPAP) are not effective ^[170]^A1b^[181]^A1b^[162]^A1b (1b).

Step 4: Monitoring and Escalation Criteria

Predictors of ICU admission in hypoxemic infants include age <2 months, pre-enrolment heart rate >160/min, pre-enrolment SpO2 <87%, previous ICU admission, and time of onset ≤2 days to presentation (OR 0.78) ^[61]^B2b (2b). Monitoring should include serial clinical severity scores, heart rate, respiratory rate, and SpO2. Escalation to HFNC or CPAP is indicated for persistent tachypnea, hypoxemia, or clinical deterioration despite low-flow oxygen.

Step 5: Discharge and Home Care

Home oxygen therapy is a feasible alternative to inpatient admission for selected infants. In a pilot RCT, 97% of infants discharged from the emergency department on home oxygen after an 8-hour observation period were successfully managed as outpatients ^[163]^A1b (1b). A separate study of home oxygen after 24 hours of inpatient therapy found that home management reduced hospital bed-days by almost 2 days (55.2 vs 96.9 hours, P = 0.001) with no serious complications ^[153]^A1b (1b). Discharge criteria include stable SpO2 ≥90% in room air, adequate feeding, and reliable caregiver support.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength of disagreement	Implication for practice
Hypertonic saline for hospitalized infants	AAP 2014 - does not recommend routine use ^[83]^A1c	Cochrane 2017 - HS reduces LOS by 0.41 days (low-quality evidence) ^[18]^A1a	Moderate (different conclusions from same evidence base)	Most guidelines advise against routine HS; clinicians may consider it in selected cases but expect marginal benefit
Oxygen saturation target	AAP 2014 - target ≥90% ^[83]^A1c	BIDS trial - target ≥90% equivalent to ≥94% for safety and efficacy ^[168]^A1b	Mild (consistent evidence)	Both targets are acceptable; the lower target reduces oxygen use without harm
High-flow nasal cannula vs CPAP	HFNC - lower treatment failure in moderate-severe (23.7% vs 42.4%) ^[158]^A1b	CPAP - improves ventilation in hypercapnic infants ^[175]^A1b	Moderate (different populations; HFNC for initial support, CPAP for escalation)	Start with HFNC; consider CPAP if HFNC fails or if hypercapnia is present

Pearl: For infants hospitalized with bronchiolitis, avoid bronchodilators, corticosteroids, , and chest physiotherapy; focus on oxygen with a target SpO2 ≥90%, use high-flow nasal cannula at 1-2 L/kg/min to reduce treatment failure, and consider home oxygen for selected patients to shorten hospital stay.

Evidence Summary for Interventions in Bronchiolitis

Intervention	Recommendation	Rationale / Key Trial	Evidence Level
Oxygen (target SpO₂ ≥90%)	Supportive care	BIDS trial: LOS equivalence ^[168]^A1b	1b
HFNC (1-2 L/kg/min)	Reduces treatment failure	Franklin et al. ^[166]^A1b; Cochrane ^[17]^A1a	1a
CPAP (mask or helmet)	Severe cases, hypercapnia	Thia et al. ^[175]^A1b; Chidini et al. ^[145]^A1b	1b
Bronchodilators (albuterol)	Not recommended	Cochrane ^[182]^A1a	1a
Corticosteroids (systemic)	Not recommended routine	Cochrane ^[185]^A1a; AAP ^[83]^A1c	1a
Hypertonic saline (3%)	Not recommended	Multiple ED RCTs negative ^[147]^A1b^[148]^A1b; inpatient benefit uncertain ^[2]^B2b	1b
Epinephrine (nebulized)	No benefit in inpatients	Skjerven et al. ^[167]^A1b	1b
Ziresovir (antiviral)	Emerging	Phase 3 trial: ↓ Wang score -0.8 points ^[34]^A1b	1b
Azithromycin	Not beneficial	Pinto et al. ^[172]^A1b	1b
Caffeine for apnea	Not effective	Alansari et al. ^[151]^A1b	1b
Chest physiotherapy	Not recommended	Combret et al. ^[181]^A1b	1b
Home oxygen therapy	Feasible in selected patients	Bajaj et al. ^[163]^A1b; Tie et al. ^[153]^A1b	1b

Dosing and Monitoring for Respiratory Support

Device	Starting settings	Target	Monitoring	Escalation criteria
Low-flow nasal cannula	0.5-2 L/min, FiO₂ titrated to SpO₂ ≥90%	SpO₂ 90%-97%	SpO₂, respiratory rate, clinical score	If SpO₂ <90% or RR >70/min, consider HFNC
High-flow nasal cannula	1-2 L/kg/min (max 20 L/min), FiO₂ to SpO₂ ≥90%	SpO₂ 90%-97%	SpO₂, RR, work of breathing, comfort	If no improvement in 1-2 h, increase flow to 2 L/kg/min; if failure, consider CPAP
CPAP (bubble/helmet)	5-8 cm H₂O, FiO₂ to SpO₂ ≥90%	SpO₂ 90%-97%	SpO₂, RR, PCO₂ (if available), skin integrity	If PCO₂ rises or clinical deterioration, consider intubation

History and Evolution of Treatment

▸Landmark trials have refuted routine use of bronchodilators, corticosteroids, hypertonic saline, and ribavirin for acute bronchiolitis.
▸High-flow nasal cannula reduces escalation of care (NNT=9) but does not shorten length of stay; CPAP improves ventilation in hypercapnic infants.
▸De-implementation strategies improve guideline adherence; oxygen saturation target of ≥90% is safe and equivalent to ≥94%.

HY High Yield: The BIDS trial (Cunningham 2015) demonstrated that an oxygen saturation target of ≥90% is as safe as ≥94% in hospitalized infants, reducing unnecessary oxygen therapy [168].

From the preceding discussion of long-term , it is clear that the acute treatment of bronchiolitis has undergone a dramatic transformation over the past three decades. What was once a field marked by empirical polypharmacy has been reshaped by a series of landmark trials that systematically refuted once-standard therapies, leaving supportive care, oxygen, hydration, and nasal suction, as the evidence-based mainstay ^[83]^A1c.

The Bronchodilator Era

In the 1990s, nebulized albuterol showed short-term improvements in clinical scores and oxygen saturation in small trials ^[199]^A1b^[200]^A1b. However, larger studies found no reduction in hospitalization or length of stay (LOS) ^[202]^A1b. Nebulized epinephrine fared similarly: the 2003 Wainwright trial found no difference in LOS ^[196]^A1b, and the 2013 Skjerven trial confirmed that racemic adrenaline was no better than saline ^[167]^A1b. The 2009 Plint trial suggested that combining epinephrine with might reduce admissions (relative risk 0.65, 95% CI 0.45-0.95), but the effect lost significance after adjustment for multiple comparisons ^[149]^A1b. Current guidelines recommend against routine bronchodilator use ^[83]^A1c^[67]^A1c.

The Corticosteroid Controversy

Systemic corticosteroids were widely prescribed despite early negative trials. The 1996 Roosevelt trial found no benefit of intramuscular dexamethasone on time to resolution of symptoms ^[197]^A1b. The 2007 Corneli trial, enrolling 600 infants with moderate-to-severe bronchiolitis, showed that a single oral dose of dexamethasone 1 mg/kg did not alter admission rates (39.7% vs 41.0%) ^[195]^A1b. A 2008 Cochrane review of 13 trials found no significant reduction in LOS (mean difference -0.38 days, 95% CI -0.81 to 0.05) ^[215]^A1a. Inhaled corticosteroids also failed: the 2000 Cade trial of nebulized budesonide showed no effect on LOS or subsequent wheezing ^[207]^A1b, and a 2011 Cochrane review confirmed no prevention of post-bronchiolitic wheezing ^[117]^A1a. The 2022 Gelbart trial found that systemic corticosteroids plus inhaled epinephrine reduced duration of positive pressure support in ICU patients (geometric mean 26 vs 40 hours; adjusted ratio 0.66, 95%) ^[86]^A1b, but this combination is not recommended outside intensive care ^[67]^A1c.

Hypertonic Saline: Promise and Disappointment

Early meta-analyses suggested that nebulized 3% hypertonic saline (HS) reduced LOS. The 2014 Wu trial reported a lower admission rate with HS (28.9% vs 42.6%; adjusted OR 0.49, 95% CI 0.28-0.86) ^[84]^A1b. However, subsequent large trials failed to replicate this. The 2015 Silver trial found no difference in median LOS (2.1 vs 2.1 days) ^[143]^A1b. The 2017 Angoulvant trial, enrolling 777 infants, showed no reduction in hospitalization (adjusted risk difference -3.2%, 95% CI - to 2.2%) ^[147]^A1b. The 2019 Jaquet-Pilloud trial also found no benefit ^[62]^A1b. A 2013 trial of 7% HS showed no improvement in severity scores ^[161]^A1b. Current guidelines do not recommend routine HS ^[83]^A1c^[67]^A1c.

Respiratory Support Revolution

The most impactful advance has been high-flow nasal cannula (HFNC) therapy. The 2018 Franklin trial, randomizing 1472 infants, found that HFNC reduced escalation of care from 23% to 12% (risk difference -11 percentage points; NNT = 9) ^[166]^A1b. However, the 2023 Kooiman trial in moderate-to-severe bronchiolitis found no difference in composite score improvement (73% vs 78%) ^[122]^A1b. Optimal flow rates remain uncertain; a 2025 trial suggested 1 L/kg/min may be as effective as higher rates with fewer adverse events ^[179]^A1b. Nasal continuous positive airway pressure (CPAP) improves ventilation in hypercapnic infants: the 2007 Thia trial showed a fall in PCO₂ of 0.92 kPa with CPAP versus a rise of 0.04 kPa with standard therapy ^[175]^A1b. Heliox, delivered via tight-fitting mask or CPAP, reduced LOS in a facemask-tolerant subgroup (1.46 vs 2.01 days) but not via nasal cannula ^[162]^A1b.

Antiviral and Immunomodulatory Agents

Ribavirin aerosol showed faster improvement in cough and recession in a 1986 trial ^[205]^A1b, but subsequent systematic reviews found no benefit, and it is not recommended ^[83]^A1c. Palivizumab, a monoclonal antibody, reduces RSV hospitalization from 10.6% to 4.8% when used as prophylaxis in high-risk infants ^[33]^A1c, but a 2019 trial found no benefit for treatment of acute RSV bronchiolitis ^[144]^A1b. The 2024 ziresovir phase 3 trial is the first antiviral to show a modest improvement in clinical score (-3.4 vs -2.7 points; difference -0.8, 95% CI -1.3 to -0.3) and viral load reduction ^[34]^A1b. Montelukast did not improve acute outcomes ^[191]^A1b but may reduce post-bronchiolitis wheezing ^[171]^A1b. Caffeine citrate failed to reduce apnea episodes ^[151]^A1b. Surfactant therapy, promising in small studies, showed no benefit in the 2026 BESS trial (median IMV duration 64.9 vs 62.0 hours) ^[178]^A1b.

De-implementation and Guideline Evolution

The 2014 AAP guideline explicitly recommended against bronchodilators, corticosteroids, chest physiotherapy, and routine chest radiography ^[83]^A1c. The 2021 Haskell trial demonstrated that targeted interventions improved compliance with these recommendations from 73% to 85% ^[146]^A1b. The BIDS trial established that an oxygen saturation target of ≥90% is as safe as ≥94% ^[168]^A1b. Intermittent is noninferior to continuous monitoring ^[165]^A1b^[193]^A1b. These shifts reflect a broader recognition that less is often more in bronchiolitis care.

Pearl: The history of bronchiolitis treatment is a cautionary tale: decades of RCTs have systematically refuted therapies once considered standard, leaving supportive care, oxygen, hydration, and nasal suction, as the evidence-based mainstay.

Key Landmark Trials Shaping Bronchiolitis Treatment

Therapy	Key Trial (Year)	Finding	Impact on Guidelines
Albuterol	Schuh 1990 ^[199]^A1b	Short-term score improvement	Not recommended ^[83]^A1c
Epinephrine	Wainwright 2003 ^[196]^A1b	No reduction in LOS	Not recommended ^[83]^A1c
Dexamethasone	Corneli 2007 ^[195]^A1b	No reduction in admission (39.7% vs 41.0%)	Not recommended ^[83]^A1c
Hypertonic saline	Angoulvant 2017 ^[147]^A1b	No reduction in hospitalization (adjusted RD -3.2%)	Not recommended ^[83]^A1c
High-flow nasal cannula	Franklin 2018 ^[166]^A1b	Reduced escalation of care (12% vs 23%; NNT=9)	Recommended for hypoxemic infants ^[67]^A1c
CPAP	Thia 2007 ^[175]^A1b	Improved PCO₂ (-0.92 vs +0.04 kPa)	Consider in hypercapnia ^[67]^A1c
Palivizumab (treatment)	Alansari 2019 ^[144]^A1b	No benefit (readmission 11% vs 9.3%)	Not recommended ^[83]^A1c
Ziresovir	Zhao 2024 ^[34]^A1b	Improved Wang score (-3.4 vs -2.7)	Not yet in guidelines
Oxygen target 90%	Cunningham 2015 ^[168]^A1b	Equivalent to 94% target	Recommended ^[83]^A1c

Growth, Development & Nutrition Impact

▸High protein intake (~3 g/kg/day) improves nitrogen balance in critically ill infants with bronchiolitis but does not reduce PICU stay and may cause gastrointestinal side effects.
▸Necrotizing enterocolitis is a rare but life-threatening complication of severe RSV bronchiolitis in term infants, manifesting with abdominal distention and ascites.
▸Inhaled corticosteroids used during RSV bronchiolitis do not affect linear growth at age 6 years.
▸Neurodevelopmental outcomes at 24 months appear similar to controls, but data in term infants are limited.

! Warning: Necrotizing enterocolitis can occur in term infants with severe RSV bronchiolitis, even without traditional risk factors. Abdominal distention, feeding intolerance, and ascites should prompt urgent evaluation [230].

From the preceding section on history and treatment evolution, it is now clear that while most infants recover from bronchiolitis without sequelae, the acute illness can significantly perturb nutritional status and, in rare cases, threaten long-term growth and development. This section examines how the metabolic stress of severe bronchiolitis alters protein-energy balance, the risk of as a nutritional catastrophe, and the evidence for long-term effects on growth and neurodevelopment.

Acute Nutritional Perturbations

Critically ill infants with bronchiolitis enter a state of negative protein balance driven by the metabolic stress response and inadequate intake ^[229]^A1b. In a double-blind RCT, de Betue et al. compared standard enteral formula (1.7 g/kg/day protein, 84 kcal/kg/day) with a protein- and energy-enriched formula (3.1 g/kg/day protein, 119 kcal/kg/day) in 18 mechanically ventilated infants with viral bronchiolitis ^[229]^A1b. Protein balance shifted from near zero (0.02 g/kg/day) with standard formula to clearly positive (0.73 g/kg/day) with the enriched formula, driven by a significant increase in protein synthesis (9.6 vs 5.2 g/kg/day) despite a concurrent increase in protein breakdown (8.9 vs 5.2 g/kg/day) ^[229]^A1b. These findings indicate that standard infant formulas may be insufficient to meet the anabolic demands of the acute phase of severe bronchiolitis.

A subsequent systematic review and meta-analysis of eight RCTs (mostly infants with bronchiolitis or after cardiac surgery) confirmed that high enteral protein intake (~3 g/kg/day) significantly increased nitrogen balance compared with recommended intake (~1.6 g/kg/day) (effect size 0.59; 95%) ^[241]^A1a. However, this metabolic improvement did not translate into a shorter PICU length of stay, and high protein intake was associated with elevated blood urea levels and, in two of four RCTs reporting tolerance, increased diarrhea or gastric retention ^[241]^A1a. The authors concluded that the optimal protein dose remains uncertain and recommended further research in the 1-2.2 g/kg/day range ^[241]^A1a.

Nutrient	Target	Rationale
Protein	2-3 g/kg/day	Achieves positive nitrogen balance; higher doses may not improve outcomes ^[229]^A1b^[241]^A1a
Energy	100-120 kcal/kg/day	Supports protein synthesis; higher intake may be needed during critical illness ^[229]^A1b
Monitoring	Blood urea, gastrointestinal tolerance (diarrhea, gastric residuals)	High protein can cause azotemia and intolerance ^[241]^A1a

Necrotizing Enterocolitis: A Rare but Severe Nutritional Complication

A rare but devastating extrapulmonary complication of severe RSV bronchiolitis is necrotizing enterocolitis (NEC) in previously healthy term and late-preterm infants. In a case series of four infants with RSV bronchiolitis and respiratory failure requiring PICU admission, all developed progressive abdominal distention, typical radiographic findings of NEC, and simple or complex ^[230]^C4. One infant required colon resection and ileostomy, two underwent peritoneal drainage for ascites, and one later developed small bowel strictures requiring delayed resection and anastomosis; one infant died of septic shock ^[230]^C4. The authors hypothesized that a dysregulated proinflammatory response in severe RSV disease alters intestinal blood flow and compromises barriers to bacterial translocation ^[230]^C4. Enteral feeding intolerance, septic ileus, and complex ascites are important clinical corollaries that should prompt evaluation for NEC, even in the absence of traditional risk factors such as prematurity or congenital heart disease ^[230]^C4.

Long-Term Growth and Neurodevelopment

The impact of bronchiolitis on long-term growth appears to be minimal when supportive care is adequate. A 6-year follow-up of the randomized trial of high-dose inhaled beclomethasone for RSV bronchiolitis found no differences in linear growth between treated and placebo groups at age 6 ^[154]^A1b. Similarly, in the trial of bovine lactoferrin for prevention of sepsis in low-birth-weight infants, growth outcomes at 24 months corrected age were similar between groups, despite the lactoferrin group having significantly less bronchiolitis (rate ratio 0.34; 95% CI 0.14-0.86) ^[37]^A1b. This suggests that while reducing bronchiolitis incidence may not independently improve growth, the illness itself does not typically cause lasting growth impairment in the absence of severe complications.

Neurodevelopmental outcomes after bronchiolitis have been less studied. In the same lactoferrin trial, the mean Mullen composite score at 24 months was 83.3 ± 13.6 in the lactoferrin group vs 82.6 ± 13.1 in the placebo group, indicating no difference ^[37]^A1b. However, this trial enrolled infants with birth weights 500-2000 g, and the neurodevelopmental impact of severe bronchiolitis in term infants remains unclear. The intense inflammatory response and hypoxia associated with severe disease could theoretically affect neurodevelopment, but direct evidence is lacking.

Pearl: In critically ill infants with bronchiolitis, achieving positive nitrogen balance requires protein intakes of 2-3 g/kg/day, but exceeding this range may not improve clinical outcomes and can cause gastrointestinal intolerance or azotemia ^[229]^A1b^[241]^A1a.

Complications

▸Acute complications include air leak syndrome (rare but serious with HFNC), NEC in severe RSV, and apnea/bradycardia in young infants.
▸Antibiotics do not prevent secondary bacterial infection and should be avoided; nasogastric hydration is as safe as IV and associated with lower ICU admission rates.
▸Post-bronchiolitis wheezing and asthma are the most common chronic sequelae, with a 3- to 5-fold increased risk of later respiratory admissions.

! Warning: High-flow nasal cannula at flows >6 L/min can cause life-threatening air leak syndrome; use the lowest effective flow and monitor for sudden clinical deterioration [245].

The growth and nutritional challenges described above compound the risk of complications in infants with bronchiolitis. These complications span acute respiratory deterioration, systemic events, iatrogenic harm, and chronic pulmonary sequelae that persist years after the index infection.

Acute Respiratory Complications

Air leak syndrome is a rare but life-threatening complication of high-flow nasal cannula (HFNC) therapy. Pneumothorax and pneumomediastinum have been reported at flows of 6-8 L/min and above, with one death in a case series ^[245]^C4. Intubation rates vary widely by center: a prospective comparison found 3% of infants in a French PICU required invasive ventilation versus 26% in a Canadian center, yet outcomes were similar ^[70]^B2b, suggesting that a less-invasive approach does not increase harm. In severe bronchiolitis, surfactant dysfunction may occur; a meta-analysis of three trials found that exogenous surfactant shortened ICU stay (mean difference -63 hours, 95% CI -130 to 4.35) but did not significantly reduce ventilation duration ^[183]^A1a.

Autonomic and Systemic Complications

Apnea and bradycardia are frequent in infants under 2 months, occurring in up to 20% of hospitalized cases ^[248]^B3b. (NEC) has been reported in previously healthy term infants with severe RSV bronchiolitis, presenting with abdominal distention, , and pneumatosis, distinct from prematurity-related NEC. In one series, one of four infants died of septic shock ^[230]^C4. Cytokine-mediated sudden death is exceptional; in two cases, IL-6 levels were >200-fold elevated with normal CRP, and autopsy showed brain edema without ^[24]^C4.

Hospital-Acquired and Iatrogenic Complications

Cutaneous pressure sores from CPAP masks are more common than with helmet interfaces (failure due to intolerance: 54% vs 17%) ^[145]^A1b. Antibiotic overuse remains prevalent despite Cochrane evidence showing no benefit: 7 RCTs (824 participants) found no reduction in length of stay or oxygen requirement with ^[255]^A1a. Nasogastric versus IV fluids have similar desaturation rates (~21.5%) and no pulmonary aspiration in a cohort of 491 infants <2 months; however, IV hydration was associated with higher ICU admission (38.5% vs 19.9%) ^[248]^B3b.

Long-Term Pulmonary Sequelae

Post-bronchiolitis wheezing and asthma are the most common late complications. Infants hospitalized for bronchiolitis have a 3- to 5-fold increased risk of subsequent respiratory admissions (HR 2.82 for any respiratory admission; HR 5.02 for wheezing) ^[39]^B2b. Early-life RSV infection, especially at 13-24 months, is associated with asthma (aHR 2.40 for HRV-RSV coinfection) ^[243]^B3b. Postinfectious bronchiolitis obliterans (PIBO) is a rare chronic obstructive pulmonary disease; in a case series, monthly IV pulse (10 mg/kg/day × 3 days) plus IVIG (1 g/kg × 2 days) for 6 months reduced wheezing episodes and hospitalizations ^[253]^B2b. Diminished lung function in prematurely born infants with RSV LRTI is predicted by higher respiratory system resistance at discharge ^[251]^B2b.

Complication	Frequency	Prevention
Air leak (pneumothorax)	Rare, case series ^[245]^C4	Avoid HFNC flows >6 L/min; monitor for clinical deterioration	Chest tube drainage, reduce PEEP
NEC	Very rare, case series ^[230]^C4	No specific prevention; monitor for abdominal distention	Bowel rest, antibiotics, surgical consult
Apnea/bradycardia	~20% in infants <2 mo ^[248]^B3b	Cardiorespiratory monitoring	Stimulation, CPAP, methylxanthines if recurrent
Secondary bacterial infection	Unclear; antibiotics often used but not evidence-based ^[255]^A1a	Avoid unnecessary antibiotics	Treat only if proven infection
Post-bronchiolitis wheezing	21.7% of hospitalized infants have subsequent respiratory admission ^[39]^B2b	No proven prevention; consider RSV prophylaxis	Inhaled bronchodilators, ICS if asthma diagnosed
PIBO	Rare	Early recognition of persistent obstruction	IV pulse methylprednisolone 10 mg/kg/day × 3 d + IVIG 1 g/kg × 2 d monthly ^[253]^B2b

Controversies and Guideline Disagreement

No major guideline disagreement exists for complications management, but the role of antibiotics in preventing secondary infection remains debated: Cochrane reviews find no benefit ^[255]^A1a, yet antibiotic prescription rates range from 34% to 99% in uncomplicated bronchiolitis ^[254]^A1a.

Pearl: The most common long-term complication of bronchiolitis is not a structural lung lesion but post-bronchiolitis wheezing, one in five hospitalized infants will have a subsequent respiratory admission by age 5 years, making it critical to counsel families about asthma risk and smoke avoidance ^[39]^B2b.

Prognosis & Natural History

▸Mortality from bronchiolitis is low (2.8 per 100,000 person-years) and stable, but ICU admission rates have more than doubled from 2004 to 2018.
▸Long-term outcomes include increased risk of asthma, especially after rhinovirus-positive bronchiolitis, and academic difficulties after PICU admission.
▸Prognostic modifiers include age <2 months, tachycardia, hypoxemia, viral etiology, and comorbidities; SARS-CoV-2 bronchiolitis is typically mild.

HY High Yield: ICU admission for bronchiolitis increased from 38 to 88 per 1000 hospitalizations between 2004 and 2018, yet mortality remained stable at 2.8 per 100,000 person-years [92].

Complications such as apnea and respiratory failure define the severe end of the bronchiolitis spectrum, but for the majority of infants the illness follows a predictable self-limited course. Understanding the natural trajectory and the factors that modify it is essential for counseling families and allocating resources.

Natural History

Symptoms typically peak on days 3 to 5 of illness, with rhinorrhea, cough, and tachypnea gradually improving over 1 to 2 weeks. Cough may persist for 2 to 3 weeks in some infants. The illness is self-limited in most previously healthy children, with hospitalization rates remaining stable at approximately 14.0 per 1000 person-years in the mid-2000s and 12.7 per 1000 person-years in 2017-2018 ^[92]^B2b.

Short-term Prognosis

Bronchiolitis accounts for 13.3% of all-cause hospitalizations and 8.4% of all-cause hospital days in children under 2 years ^[92]^B2b. Over the period 2004-2018, intensive care unit (ICU) admission increased significantly from 38.1 per 1000 hospitalizations to 87.8 per 1000 hospitalizations (annual percent change 7.2%; P < .001), while mortality remained stable at 2.8 per 100,000 person-years ^[92]^B2b. Predictors of ICU admission include age <2 months, pre-enrollment heart rate >160/min, pre-enrollment SpO2 <87%, previous ICU admission, and time of onset ≤2 days ^[61]^B2b. Among infants discharged from the emergency department, oxygen desaturations to <90% are common (64% of infants) but are not associated with increased unscheduled medical visits within 72 hours ^[94]^B2b.

Long-term Outcomes

Children hospitalized for bronchiolitis, particularly those requiring intensive care, are at risk for long-term sequelae. Infants admitted to the PICU for bronchiolitis with mechanical ventilation show poorer academic performance and school-related quality of life at age 6-12 years compared with healthy peers, with lower full-scale IQ mediating these deficits ^[262]^B2b. Viral etiology modifies long-term respiratory outcomes: rhinovirus-positive bronchiolitis is associated with higher use of asthma controller medication in the first post-hospitalization year (adjusted OR 7.5) compared with RSV-positive disease ^[269]^B2b. Early-life hospitalization for HRV or RSV, particularly at 13-24 months of age, is associated with increased asthma risk (HRV-RSV aHR 2.40; 95% CI 1.02-6.69) ^[243]^B3b. In low-resource settings, the RISC-Malawi (MUAC) score shows the highest discrimination for in-hospital mortality (AUROC 0.83; 95% CI 0.79-0.86) ^[132]^B2b.

Prognostic Modifiers

Severity is modified by age (younger infants fare worse), prematurity, congenital heart disease, chronic lung disease, immunodeficiency, and viral co-infections ^[79]^D5. SARS-CoV-2-related bronchiolitis is typically mild, with lower rates of oxygen supplementation and ventilatory support compared with other viruses ^[226]^B3b^[53]^C4. Adenovirus bronchiolitis carries a case fatality rate of 1.4% overall, rising with mechanical ventilation and complex chronic conditions ^[60]^C4. The nasopharyngeal microbiome may also influence outcomes: Moraxella abundance is higher in RSV-positive decedents compared with RSV-negative decedents in postmortem studies ^[135]^B3b.

These prognostic factors inform the risk stratification discussed in the next section on Special Populations, where specific groups, such as preterm infants, those with hemodynamically significant heart disease, and immunocompromised children, require tailored monitoring and preventive strategies.

Pearl: For infants with bronchiolitis discharged from the emergency department, home is not recommended because desaturations are common and do not predict unscheduled visits; instead, counsel families on the expected duration of cough (up to 3 weeks) and signs of respiratory distress that warrant return ^[94]^B2b.

Special Populations

▸Preterm infants, especially those with comorbidities, require closer monitoring; surfactant may shorten ICU stay but caffeine is not effective for apnea.
▸Immunocompromised patients with RSV bronchiolitis have high morbidity; supportive care is the mainstay, and ribavirin/IVIG lack proven benefit.
▸Bronchiolitis in pregnancy is rare and self-limited; management is supportive and breastfeeding is safe.

HY High Yield: Caffeine citrate (25 mg/kg IV single dose) does not reduce apnea episodes or need for ventilatory support in bronchiolitis; avoid routine use [13, 151].

These prognostic associations underscore the need to tailor across populations whose developmental stage, immune status, or comorbidities alter the risk‑benefit balance of interventions.

Pediatrics

Preterm infants are at heightened risk for severe bronchiolitis. Compared with term infants, those born before 32 weeks’ gestation have more hypoxia, longer hospital stays, and more frequent antibiotic use ^[276]^B2b. Late‑preterm infants (gestational age 34-36.9 weeks) have 35% higher odds of asthma by age 5 years ^[274]^B2b.

Caffeine for apnea - a single 25 mg/kg IV dose of caffeine citrate did not reduce the time to a 24‑hour apnea‑free period, the need for noninvasive ventilation, or length of stay in a randomized trial of 90 infants ^[151]^A1b. A systematic review with meta‑analysis confirmed no significant effect on duration of noninvasive ventilation or ICU stay, though a trend toward reduced total respiratory support duration was noted (mean difference -2.63 days, 95% CI -5.61 to 0.34) ^[13]^A1a. Routine use of caffeine is not supported.

Surfactant therapy in mechanically ventilated infants has been evaluated in three small RCTs (n = 79). Pooled analysis showed a reduction in ICU length of stay (mean difference -3.31 days, 95% CI -6.38 to -0.25) but no significant difference in duration of mechanical ventilation ^[183]^A1a^[189]^A1a.

Respiratory support - high‑flow nasal cannula (HFNC) at 2 L/kg/min did not improve a composite dyspnea score within 24 hours compared with low‑flow oxygen (≤ 3 L/min) in a multicenter trial of 107 children ^[122]^A1b. In a separate trial, HFNC reduced treatment failure (14% vs 33%) but did not shorten time to weaning ^[150]^A1b.

Medication modifications - nebulized 3% hypertonic saline does not reduce hospital admission rates in the emergency department (adjusted risk difference -3.2%) and causes more cough ^[147]^A1b^[148]^A1b. Combined systemic corticosteroids and inhaled epinephrine shortened the duration of positive pressure support in the ICU (geometric mean 26 vs 40 hours; adjusted ratio 0.66) ^[86]^A1b. Ziresovir, a novel RSV inhibitor, reduced the Wang bronchiolitis score on day 3 (difference -0.8 points, 95% CI -1.3 to -0.3) in hospitalized infants ^[34]^A1b.

Developmental impact - children admitted to the PICU for bronchiolitis had lower academic performance and school‑related quality of life at age 6-12 years, mediated by lower full‑scale IQ ^[262]^B2b.

Pregnancy

Data on bronchiolitis in pregnancy are scarce. RSV infection in pregnant women is usually mild and self‑limited, presenting as an upper respiratory infection. Management is limited to supportive care - hydration, antipyretics, and oxygen if needed. No antiviral or immunomodulatory therapy is indicated. is safe and should be encouraged, as it provides passive immunity to the infant.

Elderly

Respiratory syncytial virus and human metapneumovirus (hMPV) cause substantial lower respiratory tract illness in older adults, particularly those with chronic obstructive pulmonary disease, congestive heart failure, or frailty ^[118]^D5. Bronchiolitis‑like presentations with hypoxia and prolonged cough are common. Diagnosis is often missed because viral testing is not routinely performed. Treatment is supportive; no specific antiviral is recommended. Outbreaks in long‑term care facilities have been associated with mortality up to 50% ^[118]^D5.

Immunocompromised

Immunocompromised children and adults - including hematopoietic stem cell transplant (HSCT) recipients, those with primary immunodeficiency, or organ transplant recipients - are at risk for severe, prolonged RSV infection that can progress to pneumonia and respiratory failure ^[118]^D5. hMPV has been linked to severe idiopathic pneumonia in HSCT recipients ^[118]^D5.

Management - supportive care with oxygen and respiratory support is the mainstay. Ribavirin (aerosolized or oral) has been used in this population, but a Cochrane review found no statistically significant benefit of intravenous immunoglobulin (IVIG) added to supportive care ^[268]^A1a. Fungal co‑infection is an independent predictor of septic shock in pediatric RSV bronchiolitis (aOR 9.01) ^[68]^B2b.

Prophylaxis - palivizumab is recommended for high‑risk infants (e.g., preterm, congenital heart disease, chronic lung disease) but is not indicated for treatment or for immunocompromised adults ^[31]^A1c.

Pearl: In preterm infants with bronchiolitis, caffeine does not reduce apnea episodes or need for ventilation; avoid its routine use ^[13]^A1a^[151]^A1b.

Prevention, Screening & Surveillance

▸Nirsevimab, a single-dose monoclonal antibody, reduces RSV-associated hospitalizations by 74% and PICU admissions by 85% in real-world studies [91][280].
▸Maternal RSV vaccination (RSVPreF3-Mat) shows robust antibody transfer but requires careful risk-benefit assessment due to preterm birth signal in healthy women [224].
▸Nonpharmaceutical interventions (hand hygiene, avoidance of tobacco smoke) remain foundational; breastfeeding and bovine lactoferrin [37] may offer additional benefit.

HY High Yield: Nirsevimab is a game-changer: one dose for the season, applicable to all infants, not just high-risk groups. Maternal RSV vaccine is an emerging option but is not yet standard for all pregnant women.

Building on the identification of high-risk infants in the preceding section, prevention of bronchiolitis rests on three pillars: passive immunoprophylaxis, infection control, and, increasingly, maternal vaccination. The most consequential shift in recent years has been the introduction of nirsevimab, a long-acting monoclonal antibody against the RSV prefusion F protein, which has transformed the prevention landscape for all infants, not just those with comorbidities.

Immunization and Monoclonal Antibody Prophylaxis

Nirsevimab is now recommended for all infants <8 months of age entering their first RSV season, and for high-risk children aged 8-19 months entering their second season [label]. A single intramuscular dose provides season-long protection. Real-world effectiveness data from Catalonia showed that nirsevimab reduced RSV-associated hospitalizations by 74% (adjusted HR 0.26, 95% CI 0.17-0.39) and PICU admissions by 85% (adjusted HR 0.15) ^[91]^B2b. A test-negative case-control study in Lombardy reported 82% effectiveness against RSV infection and 78% against RSV-related hospitalization ^[280]^B3b. In a French multicenter study of infants <3 months, nirsevimab demonstrated 53.5% adjusted effectiveness in reducing all-cause bronchiolitis hospitalizations and 51.1% reduction in PICU admissions ^[282]^B2b. A single-center Italian cohort with 87.5% immunization coverage observed a halving of absolute bronchiolitis admissions and a significant reduction in RSV positivity (OR 0.159) ^[55]^B2b. Parental acceptance is influenced by trust in the pediatrician’s recommendation and fear of RSV disease; misinformation about nirsevimab being a “new understudied vaccine” similar to vaccines is a common barrier ^[125]^D5. Starting conversations during pregnancy and leveraging clinician trust improve uptake ^[125]^D5.

Palivizumab remains an option for select high-risk infants (e.g., those with hemodynamically significant congenital heart disease, chronic lung disease of prematurity, or born at <29 weeks’ gestation), but its monthly dosing schedule and narrower indication have been largely superseded by nirsevimab’s broader eligibility ^[31]^A1c. The AAP’s 2006 guideline recommended palivizumab for these groups based on reduced RSV hospitalization rates ^[31]^A1c.

Maternal RSV vaccination is an emerging strategy. A phase 3 trial of the RSV prefusion F protein maternal vaccine (RSVPreF3-Mat) in high-risk pregnant women (obstetric complications, HIV, or adolescents) demonstrated an acceptable safety profile with robust immune responses and placental transfer: geometric mean ratio of neutralizing antibody titers at delivery over pre-vaccination was 8.87-fold for RSV-A and 8.21-fold for RSV-B, with a placental transfer ratio of 1.33 ^[224]^A1b. Preterm birth rates were balanced between groups (18.2% vs. 19.7%), though enrollment was stopped early due to increased preterm birth risk observed in a separate trial of healthy pregnant women ^[224]^A1b. This underscores the need for careful risk-benefit assessment in maternal immunization programs.

Other Prevention Strategies

Infection control measures remain critical. During the COVID-19 pandemic, nonpharmaceutical interventions (NPIs) reduced bronchiolitis cases by 65-76% across European pediatric EDs, but their lifting led to a 329% surge in bronchiolitis, suggesting an “immune debt” phenomenon ^[273]^B2c. Hand hygiene, respiratory etiquette, and avoidance of tobacco smoke exposure are standard recommendations ^[31]^A1c. has been associated with reduced severity, though not consistently with prevention of infection ^[31]^A1c.

Bovine lactoferrin supplementation in neonates weighing <2000 g did not reduce late-onset sepsis but was associated with significantly less bronchiolitis during 2-year follow-up (rate ratio 0.34, 95%) ^[37]^A1b. This finding requires replication before clinical adoption.

Altitude above 2500 m is a modest independent predictor of RSV hospitalization (25% increase per 1000 m in infants <1 year) ^[278]^B2c. Clinicians in high-altitude regions should counsel families about early recognition of respiratory distress.

Screening and Surveillance

No universal screening program for RSV or other bronchiolitis viruses exists. Surveillance is targeted: infants with comorbidities (congenital heart disease, chronic lung disease, immunodeficiency) should have RSV testing considered during respiratory illness to guide cohorting and prophylaxis decisions ^[31]^A1c. Local RSV season surveillance networks help optimize timing of monoclonal antibody administration, as seasonality has become highly atypical after the COVID-19 pandemic, with onset shifting to summer/fall in many regions ^[59]^B2b^[81]^B2b.

Vaccination status assessment is a quality measure: children with acute respiratory tract illness whose vaccination status is documented as not up-to-date have higher odds of undergoing laboratory testing (blood cultures, CRP, influenza testing) compared with those who are up-to-date, after adjusting for severity ^[277]^B2b. Ensuring routine immunizations are current reduces unnecessary diagnostic workup.

Patient Education

Parents should be counseled that RSV is the most common cause of bronchiolitis, that most cases are self-limited, and that nirsevimab offers safe, effective prevention. Key messages: a single dose protects for the entire RSV season; common side effects are mild (fever, injection site reaction); and the monoclonal antibody does not contain live virus and cannot cause infection ^[125]^D5. For families declining nirsevimab, emphasis on hand hygiene, avoiding sick contacts, and breastfeeding remains important.

Pearl: Nirsevimab is now the standard of care for all infants <8 months entering their first RSV season, its real-world effectiveness (~74% reduction in RSV hospitalizations) and single-dose convenience make it superior to palivizumab for most infants, and maternal RSV vaccination remains an evolving complement with a favorable safety profile in high-risk pregnancies.

Comparison of RSV Immunoprophylaxis Options

Agent	Indication	Schedule	RSV hospitalization reduction	Key evidence
Nirsevimab	All infants <8 mo entering first RSV season; high-risk 8-19 mo entering second season	Single IM dose	74% (aHR 0.26) ^[91]^B2b; 82% vs RSV infection ^[280]^B3b	Real-world cohort ^[91]^B2b, test-negative case-control ^[280]^B3b
Palivizumab	High-risk only (CLD, CHD, <29 wk GA)	Monthly IM × 5 doses	~55% in high-risk infants ^[31]^A1c	AAP guideline ^[31]^A1c
RSVPreF3-Mat (maternal vaccine)	High-risk pregnant women (obstetric complications, HIV, adolescents)	Single IM dose at 24-36 wk	Not directly measured; placental transfer ratio 1.33 ^[224]^A1b	Phase 3 trial ^[224]^A1b

References

[1]
McDaniel CE, Ralston S, Lucas B et al.. “Association of Diagnostic Criteria With Urinary Tract Infection Prevalence in Bronchiolitis: A Systematic Review and Meta-analysis.” JAMA pediatrics (2019). PMID: 30688987 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Diagnosis & Workup
[2]
Brooks CG, Harrison WN, Ralston SL. “Association Between Hypertonic Saline and Hospital Length of Stay in Acute Viral Bronchiolitis: A Reanalysis of 2 Meta-analyses.” JAMA pediatrics (2016). PMID: 27088767 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature, Clinical Presentation, Diagnosis & Workup, Long-term & Definitive Management
[3]
Fujiogi M, Goto T, Yasunaga H et al.. “Trends in Bronchiolitis Hospitalizations in the United States: 2000-2016.” Pediatrics (2019). PMID: 31699829 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors
[4]
Wolf ER, Richards A, Lavallee M et al.. “Patient, Provider, and Health Care System Characteristics Associated With Overuse in Bronchiolitis.” Pediatrics (2021). PMID: 34556548 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup
[5]
Hasegawa K, Tsugawa Y, Brown DF et al.. “Trends in bronchiolitis hospitalizations in the United States, 2000-2009.” Pediatrics (2013). PMID: 23733801 ↗
L2OTHERCited in: Definition, Classification & Nomenclature
[6]
Pelletier AJ, Mansbach JM, Camargo CA. “Direct medical costs of bronchiolitis hospitalizations in the United States.” Pediatrics (2006). PMID: 17142527 ↗
L2OTHERCited in: Definition, Classification & Nomenclature
[7]
Parikh K, Hall M, Mittal V et al.. “Establishing benchmarks for the hospitalized care of children with asthma, bronchiolitis, and pneumonia.” Pediatrics (2014). PMID: 25136044 ↗
L2OTHERCited in: Definition, Classification & Nomenclature
[8]
Shanthikumar S, Gower WA, Srinivasan S et al.. “Detection of Bronchiolitis Obliterans Syndrome after Pediatric Hematopoietic Stem Cell Transplantation: An Official American Thoracic Society Clinical Practice Guideline.” American journal of respiratory and critical care medicine (2024). PMID: 38889365 ↗
L1GUIDELINECited in: Definition, Classification & Nomenclature, Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization, Long-term & Definitive Management
[9]
Ahrens KA, Janevic T, Strumpf EC et al.. “Paid Family Leave and Prevention of Acute Respiratory Infections in Young Infants.” JAMA pediatrics (2024). PMID: 39186259 ↗
L2OTHERCited in: Definition, Classification & Nomenclature
[10]
Ramsden V, Babl FE, Haskell L et al.. “Sustainability of the de-implementation of low-value care in infants with bronchiolitis: 2-year follow-up of a cluster randomised controlled trial.” BMJ quality & safety (2026). PMID: 40651808 ↗
L2RCTCited in: Definition, Classification & Nomenclature, Long-term & Definitive Management
[11]
Ramsden V, Babl FE, Dalziel SR et al.. “Sustainability of evidence-based practices in the management of infants with bronchiolitis in hospital settings - a PREDICT study protocol.” BMC health services research (2022). PMID: 36038929 ↗
L5TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature
[12]
Wang CN, Huttner BD, Magrini N et al.. “Pediatric Antibiotic Prescribing in China According to the 2019 World Health Organization Access, Watch, and Reserve (AWaRe) Antibiotic Categories.” The Journal of pediatrics (2020). PMID: 32093934 ↗
L2OTHERCited in: Definition, Classification & Nomenclature
[13]
Brossier DW, Cerasuolo D, Briant AR et al.. “Caffeine and other methylxanthines' impact on bronchiolitis-related apnea in under 12-months-old children-a systematic review with meta-analyses.” European journal of pediatrics (2026). PMID: 41653310 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Special Populations
[14]
Manti S, Gambadauro A, Ruggeri P et al.. “Application of the TIDieR checklist to improve the HFNC use in bronchiolitis management.” European journal of pediatrics (2024). PMID: 39690333 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature
[15]
Green CA, Yeates D, Goldacre A et al.. “Admission to hospital for bronchiolitis in England: trends over five decades, geographical variation and association with perinatal characteristics and subsequent asthma.” Archives of disease in childhood (2015). PMID: 26342094 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Special Populations
[16]
Foley DA, Phuong LK, Peplinski J et al.. “Examining the interseasonal resurgence of respiratory syncytial virus in Western Australia.” Archives of disease in childhood (2021). PMID: 34433552 ↗
L3OTHERCited in: Definition, Classification & Nomenclature, Clinical Presentation
[17]
Armarego M, Forde H, Wills K et al.. “High-flow nasal cannula therapy for infants with bronchiolitis.” The Cochrane database of systematic reviews (2024). PMID: 38506440 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Diagnosis & Workup, Long-term & Definitive Management, Complications
[18]
Zhang L, Mendoza-Sassi RA, Wainwright C et al.. “Nebulised hypertonic saline solution for acute bronchiolitis in infants.” The Cochrane database of systematic reviews (2017). PMID: 29265171 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Long-term & Definitive Management
[19]
Garcia-Mauriño C, Moore-Clingenpeel M, Wallihan R et al.. “Discharge Criteria for Bronchiolitis: An Unmet Need.” The Pediatric infectious disease journal (2018). PMID: 29189658 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Special Populations
[20]
Resch B, Puchas C, Resch E et al.. “Epidemiology of Respiratory Syncytial Virus-related Hospitalizations and the Influence of Viral Coinfections in Southern Austria in a 7-year Period.” The Pediatric infectious disease journal (2020). PMID: 31651808 ↗
L3OTHERCited in: Definition, Classification & Nomenclature, History and Evolution of Treatment
[21]
Jartti T, Lehtinen P, Vuorinen T et al.. “Bronchiolitis: age and previous wheezing episodes are linked to viral etiology and atopic characteristics.” The Pediatric infectious disease journal (2009). PMID: 19258922 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, History and Evolution of Treatment, Special Populations
[22]
Muñoz-Quiles C, López-Lacort M, Úbeda-Sansano I et al.. “Population-based Analysis of Bronchiolitis Epidemiology in Valencia, Spain.” The Pediatric infectious disease journal (2016). PMID: 26658376 ↗
L3OTHERCited in: Definition, Classification & Nomenclature
[23]
Piedra PA, Mansbach JM, Jewell AM et al.. “Bordetella pertussis is an uncommon pathogen in children hospitalized with bronchiolitis during the winter season.” The Pediatric infectious disease journal (2015). PMID: 25970109 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup
[24]
Kakimoto Y, Seto Y, Ochiai E et al.. “Cytokine Elevation in Sudden Death With Respiratory Syncytial Virus: A Case Report of 2 Children.” Pediatrics (2016). PMID: 27940684 ↗
L4CASE_REPORTCited in: Pathophysiology & Developmental Mechanism, Complications
[25]
Balekian DS, Linnemann RW, Castro VM et al.. “Pre-birth cohort study of atopic dermatitis and severe bronchiolitis during infancy.” Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (2016). PMID: 26766307 ↗
L2COHORTCited in: Pathophysiology & Developmental Mechanism
[26]
Manti S, Cuppari C, Lanzafame A et al.. “Detection of respiratory syncytial virus (RSV) at birth in a newborn with respiratory distress.” Pediatric pulmonology (2017). PMID: 28834426 ↗
L4CASE_REPORTCited in: Pathophysiology & Developmental Mechanism
[27]
Piedimonte G, Harford TJ. “Effects of maternal-fetal transmission of viruses and other environmental agents on lung development.” Pediatric research (2019). PMID: 31698410 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Developmental Mechanism
[28]
Vu LD, Saravia J, Jaligama S et al.. “Deficiency in ST2 signaling ameliorates RSV-associated pulmonary hypertension.” American journal of physiology. Heart and circulatory physiology (2021). PMID: 34170196 ↗
L5OTHERCited in: Pathophysiology & Developmental Mechanism
[29]
Ackermann MR. “Lamb model of respiratory syncytial virus-associated lung disease: insights to pathogenesis and novel treatments.” ILAR journal (2014). PMID: 24936027 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Developmental Mechanism
[30]
Arkwright PD, Abinun M. “Recently identified factors predisposing children to infectious diseases.” Current opinion in infectious diseases (2008). PMID: 18448964 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Developmental Mechanism
[31]
. “Diagnosis and management of bronchiolitis.” Pediatrics (2006). PMID: 17015575 ↗
L1GUIDELINECited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization, Long-term & Definitive Management, History and Evolution of Treatment, Special Populations, Prevention, Screening & Surveillance
[32]
. “Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.” Pediatrics (2014). PMID: 25070315 ↗
L1GUIDELINECited in: Epidemiology, Etiology & Risk Factors, Prognosis & Natural History
[33]
. “Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.” Pediatrics (2014). PMID: 25070304 ↗
L1GUIDELINECited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, Prognosis & Natural History
[34]
Zhao S, Shang Y, Yin Y et al.. “Ziresovir in Hospitalized Infants with Respiratory Syncytial Virus Infection.” The New England journal of medicine (2024). PMID: 39321361 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Severity Grading, Staging & Risk Stratification, Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization, Long-term & Definitive Management, History and Evolution of Treatment, Special Populations
[35]
Bloemers BL, van Furth AM, Weijerman ME et al.. “Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis--a prospective birth-cohort study.” Pediatrics (2007). PMID: 17908728 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors
[36]
Birch EE, Khoury JC, Berseth CL et al.. “The impact of early nutrition on incidence of allergic manifestations and common respiratory illnesses in children.” The Journal of pediatrics (2010). PMID: 20227721 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Growth, Development & Nutrition Impact
[37]
Ochoa TJ, Zegarra J, Bellomo S et al.. “Randomized Controlled Trial of Bovine Lactoferrin for Prevention of Sepsis and Neurodevelopment Impairment in Infants Weighing Less Than 2000 Grams.” The Journal of pediatrics (2020). PMID: 32037149 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, Growth, Development & Nutrition Impact, Prognosis & Natural History, Prevention, Screening & Surveillance
[38]
Sismanlar T, Aslan AT, Turktas H et al.. “Respiratory Bronchiolitis-Associated Interstitial Lung Disease in Childhood: New Sequela of Smoking.” Pediatrics (2015). PMID: 26347438 ↗
L4CASE_REPORTCited in: Epidemiology, Etiology & Risk Factors, Growth, Development & Nutrition Impact
[39]
Skirrow H, Wincott T, Cecil E et al.. “Preschool respiratory hospital admissions following infant bronchiolitis: a birth cohort study.” Archives of disease in childhood (2019). PMID: 30842095 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Complications, Special Populations
[40]
Coon ER, Young PC, Quinonez RA et al.. “Update on Pediatric Overuse.” Pediatrics (2017). PMID: 28049113 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Special Populations
[41]
Baillie VL, Olwagen CP, Madhi SA. “Review on Clinical and Molecular Epidemiology of Human Rhinovirus-Associated Lower Respiratory Tract Infections in African and Southeast Asian Children.” The Pediatric infectious disease journal (2018). PMID: 29893746 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Special Populations, Prevention, Screening & Surveillance
[42]
Vihikangas T, Palmu S, Koivisto AM et al.. “Changes in Bronchiolitis Incidence During the Last Two Decades in Tampere, Finland: A Retrospective Study.” The Pediatric infectious disease journal (2022). PMID: 35895894 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Special Populations
[43]
Wang YC, Tsai CS, Yang YH et al.. “Association Between Enterovirus Infection and Asthma in Children: A 16-year Nationwide Population-based Cohort Study.” The Pediatric infectious disease journal (2018). PMID: 29373474 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Complications
[44]
Coon ER, Young PC, Quinonez RA et al.. “2017 Update on Pediatric Medical Overuse: A Review.” JAMA pediatrics (2018). PMID: 29582079 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Growth, Development & Nutrition Impact, Special Populations
[45]
Hansel TT, Johnston SL, Openshaw PJ. “Microbes and mucosal immune responses in asthma.” Lancet (London, England) (2013). PMID: 23428115 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Special Populations
[46]
Morikawa Y, Morimoto K, Kodani T et al.. “Safety and efficacy of a helium-oxygen mix for pediatric respiratory failure associated with anatomical and functional stenotic lesions of the airway: a phase II clinical trial.” Respiratory medicine (2025). PMID: 41412268 ↗
L4TRIAL_NONRANDOMCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup
[47]
Doumat G, Mehta GD, Espinola JA et al.. “Race-Neutral Equations and Pulmonary Function Test Interpretation in Two Pediatric Cohorts.” The Journal of pediatrics (2024). PMID: 38815738 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity Grading, Staging & Risk Stratification, Growth, Development & Nutrition Impact
[48]
Schuh S, Kwong JC, Holder L et al.. “Predictors of Critical Care and Mortality in Bronchiolitis after Emergency Department Discharge.” The Journal of pediatrics (2018). PMID: 29747934 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation
[49]
Deschamps J, Boucekine M, Fayol L et al.. “Neighborhood Disadvantage and Early Respiratory Outcomes in Very Preterm Infants with Bronchopulmonary Dysplasia.” The Journal of pediatrics (2021). PMID: 34216631 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors
[50]
Laugier O, Garcia P, Boucékine M et al.. “Influence of Socioeconomic Context on the Rehospitalization Rates of Infants Born Preterm.” The Journal of pediatrics (2017). PMID: 28893384 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors
[51]
Khales P, Razizadeh MH, Ghorbani S et al.. “The prevalence and role of human respiratory syncytial virus in pediatric respiratory tract infections: a systematic review and meta-analysis of global data.” EClinicalMedicine (2026). PMID: 41908856 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Prevention, Screening & Surveillance
[52]
Pang Z, Guo N, Han L et al.. “Epidemiological characteristics and clinical correlations of human metapneumovirus (HMPV) infection in children aged 0-14 years in China: a systematic review and meta-analysis.” BMC public health (2026). PMID: 41527080 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Special Populations, Prevention, Screening & Surveillance
[53]
Cozzi G, Cortellazzo Wiel L, Amaddeo A et al.. “Prevalence of SARS-CoV-2 positivity in infants with bronchiolitis: a multicentre international study.” Archives of disease in childhood (2022). PMID: 35705371 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, History and Evolution of Treatment, Prognosis & Natural History
[54]
Aik J, Lau HX, Woo M et al.. “Meteorological, ozone, maternal and individual-level risk factors for childhood diseases in Singapore: A prospective birth cohort study from 2009 to 2019.” Ecotoxicology and environmental safety (2026). PMID: 42066443 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Special Populations
[55]
Castagno E, Aschieri C, Ferri I et al.. “Epidemiological Impact of Nirsevimab on Admissions for Bronchiolitis in a Pediatric Emergency Department: A Single-Center Cohort Study.” Viruses (2026). PMID: 42043258 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Special Populations, Prevention, Screening & Surveillance
[56]
Meyer SIR, Albertsen BK, Skipper MT et al.. “Pulmonary Function Deficit and Clinical Associations in Childhood Acute Lymphoblastic Leukaemia Survivors: A National Retrospective ALL-STAR Lungs Cohort Study.” Pediatric pulmonology (2026). PMID: 41969139 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Prognosis & Natural History
[57]
Dallagiacoma G, Lundholm C, Smew AI et al.. “Risk factors for severe outcomes of respiratory syncytial virus infection in children: a nationwide cohort study in Sweden.” The Lancet regional health. Europe (2025). PMID: 41262420 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Prevention, Screening & Surveillance
[58]
Ma HY, Lin IF, Liu YC et al.. “Risk Factors for Severe Respiratory Syncytial Virus Infection in Hospitalized Children.” The Pediatric infectious disease journal (2024). PMID: 38295229 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Special Populations
[59]
Daniels D, Wang D, Suryadevara M et al.. “Epidemiology of RSV Bronchiolitis Among Young Children in Central New York Before and After the Onset of the COVID-19 Pandemic.” The Pediatric infectious disease journal (2023). PMID: 37725814 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Prevention, Screening & Surveillance
[60]
Totapally BR, Totapalli S, Sendi P et al.. “Epidemiology of Adenovirus Infection in Hospitalized Children in the United States From 1997 to 2019.” The Pediatric infectious disease journal (2024). PMID: 38621167 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Prognosis & Natural History
[61]
Franklin D, Babl FE, Neutze J et al.. “Predictors of Intensive Care Admission in Hypoxemic Bronchiolitis Infants, Secondary Analysis of a Randomized Trial.” The Journal of pediatrics (2022). PMID: 36528052 ↗
L2RCTCited in: Clinical Presentation, Long-term & Definitive Management, History and Evolution of Treatment, Prognosis & Natural History, Special Populations
[62]
Jaquet-Pilloud R, Verga ME, Russo M et al.. “Nebulised hypertonic saline in moderate-to-severe bronchiolitis: a randomised clinical trial.” Archives of disease in childhood (2019). PMID: 31488402 ↗
L1RCTCited in: Clinical Presentation, Diagnosis & Workup, Long-term & Definitive Management, History and Evolution of Treatment
[63]
Viehl L, Estabrook M, Bhalla S et al.. “First Time Wheezing in a 2-Year-Old.” Pediatrics (2021). PMID: 34158315 ↗
L4CASE_REPORTCited in: Clinical Presentation, Diagnosis & Workup
[64]
Shanahan KH, Monuteaux MC, Nagler J et al.. “Early Use of Bronchodilators and Outcomes in Bronchiolitis.” Pediatrics (2021). PMID: 34230092 ↗
L2OTHERCited in: Clinical Presentation
[65]
Lew A, House S, Flaherty B et al.. “Trends in Lower Respiratory Tract Diagnoses and Nonrecommended Bronchiolitis Therapies.” Pediatrics (2025). PMID: 41151618 ↗
L2OTHERCited in: Clinical Presentation
[66]
Cheuk DK, Tang IW, Chan KH et al.. “Rhinovirus infection in hospitalized children in Hong Kong: a prospective study.” The Pediatric infectious disease journal (2007). PMID: 17984805 ↗
L2COHORTCited in: Clinical Presentation
[67]
Borland ML, Loveys K, Babl FE et al.. “Australasian Bronchiolitis Guideline: 2025 Update.” Journal of paediatrics and child health (2025). PMID: 40685806 ↗
L1GUIDELINECited in: Clinical Presentation, History and Evolution of Treatment
[68]
Dong J, Ouyang Y, Ni J et al.. “Development and internal validation of a clinical prediction model for septic shock in pediatric respiratory syncytial virus bronchiolitis based on routine blood biomarkers and concomitant fungal infection.” Frontiers in cellular and infection microbiology (2026). PMID: 42221582 ↗
L2TRIAL_NONRANDOMCited in: Clinical Presentation, Diagnosis & Workup, Severity Grading, Staging & Risk Stratification, Growth, Development & Nutrition Impact, Special Populations
[69]
McLaren SH, Camargo CA, Florin TA et al.. “Young infants with bronchiolitis at low risk of respiratory deterioration in an urban, academic emergency department: prospective cohort study protocol.” BMJ open (2025). PMID: 40858371 ↗
L5TRIAL_NONRANDOMCited in: Clinical Presentation, History and Evolution of Treatment, Growth, Development & Nutrition Impact
[70]
Essouri S, Baudin F, Chevret L et al.. “Variability of Care in Infants with Severe Bronchiolitis: Less-Invasive Respiratory Management Leads to Similar Outcomes.” The Journal of pediatrics (2017). PMID: 28602381 ↗
L2OTHERCited in: Clinical Presentation, Severity Grading, Staging & Risk Stratification, Complications
[71]
Rao S, Armistead I, Tyler A et al.. “Respiratory Syncytial Virus, Influenza, and Coronavirus Disease 2019 Hospitalizations in Children in Colorado During the 2021-2022 Respiratory Virus Season.” The Journal of pediatrics (2023). PMID: 37201680 ↗
L2OTHERCited in: Clinical Presentation, Diagnosis & Workup, Prevention, Screening & Surveillance
[72]
Schuh S, Lalani A, Allen U et al.. “Evaluation of the utility of radiography in acute bronchiolitis.” The Journal of pediatrics (2007). PMID: 17382126 ↗
L2OTHERCited in: Clinical Presentation
[73]
Heath A, Rios D, Vogel KI et al.. “A randomised controlled trial comparing epinephrine and dexamethasone to placebo in the treatment of infants with bronchiolitis (BIPED study): a statistical analysis plan.” Trials (2025). PMID: 41225556 ↗
L5RCTCited in: Clinical Presentation
[74]
Sharan RV, Rahimi-Ardabili H. “Detecting acute respiratory diseases in the pediatric population using cough sound features and machine learning: A systematic review.” International journal of medical informatics (2023). PMID: 37224643 ↗
L2SR_OBSCited in: Clinical Presentation
[75]
Thouvenin G, Abou Taam R, Flamein F et al.. “Characteristics of disorders associated with genetic mutations of surfactant protein C.” Archives of disease in childhood (2010). PMID: 20403820 ↗
L4OTHERCited in: Clinical Presentation, Growth, Development & Nutrition Impact
[76]
Murch H, Oakley J, Pierrepoint M et al.. “Using multifaceted education to improve management in acute viral bronchiolitis.” Archives of disease in childhood (2015). PMID: 25888695 ↗
L4OTHERCited in: Clinical Presentation, Diagnosis & Workup
[77]
Hartling L, Bialy LM, Vandermeer B et al.. “Epinephrine for bronchiolitis.” The Cochrane database of systematic reviews (2011). PMID: 21678340 ↗
L1SR_OBSCited in: Clinical Presentation
[78]
Umoren R, Odey F, Meremikwu MM. “Steam inhalation or humidified oxygen for acute bronchiolitis in children up to three years of age.” The Cochrane database of systematic reviews (2011). PMID: 21249676 ↗
L1SR_OBSCited in: Clinical Presentation
[79]
Diaz-Diaz A, Garcia-Maurino C, Jordan-Villegas A et al.. “Viral Bacterial Interactions in Children: Impact on Clinical Outcomes.” The Pediatric infectious disease journal (2019). PMID: 31205238 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Severity Grading, Staging & Risk Stratification, Complications, Prognosis & Natural History, Special Populations
[80]
Moro MR, Bonville CA, Suryadevara M et al.. “Clinical features, adenovirus types, and local production of inflammatory mediators in adenovirus infections.” The Pediatric infectious disease journal (2009). PMID: 19319023 ↗
L4OTHERCited in: Clinical Presentation
[81]
Nenna R, Pierangeli A, Matera L et al.. “Respiratory Syncytial Virus Bronchiolitis Before and After COVID-19 Pandemic: Has the Immunity Debt Been Paid Off?” The Pediatric infectious disease journal (2024). PMID: 38451927 ↗
L2OTHERCited in: Clinical Presentation, Severity Grading, Staging & Risk Stratification, Prevention, Screening & Surveillance
[82]
Kadmon G, Feinstein Y, Lazar I et al.. “Variability of Care of Infants With Severe Respiratory Syncytial Virus Bronchiolitis: A Multicenter Study.” The Pediatric infectious disease journal (2020). PMID: 32304465 ↗
L4OTHERCited in: Clinical Presentation, Diagnosis & Workup
[83]
Ralston SL, Lieberthal AS, Meissner HC et al.. “Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis.” Pediatrics (2014). PMID: 25349312 ↗
L1GUIDELINECited in: Diagnosis & Workup, Long-term & Definitive Management, History and Evolution of Treatment
[84]
Wu S, Baker C, Lang ME et al.. “Nebulized hypertonic saline for bronchiolitis: a randomized clinical trial.” JAMA pediatrics (2014). PMID: 24862623 ↗
L1RCTCited in: Diagnosis & Workup, Long-term & Definitive Management, History and Evolution of Treatment
[85]
Mittal V, Hall M, Morse R et al.. “Impact of inpatient bronchiolitis clinical practice guideline implementation on testing and treatment.” The Journal of pediatrics (2014). PMID: 24961787 ↗
L2GUIDELINECited in: Diagnosis & Workup
[86]
Gelbart B, McSharry B, Delzoppo C et al.. “Pragmatic Randomized Trial of Corticosteroids and Inhaled Epinephrine for Bronchiolitis in Children in Intensive Care.” The Journal of pediatrics (2022). PMID: 35093318 ↗
L1RCTCited in: Diagnosis & Workup, Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization, Long-term & Definitive Management, History and Evolution of Treatment, Prognosis & Natural History, Special Populations
[87]
Zorc JJ, Hall CB. “Bronchiolitis: recent evidence on diagnosis and management.” Pediatrics (2010). PMID: 20100768 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Prevention, Screening & Surveillance
[88]
Frazier SB, Walls C, Jain S et al.. “Reducing Chest Radiographs in Bronchiolitis Through High-Reliability Interventions.” Pediatrics (2021). PMID: 34344801 ↗
L4OTHERCited in: Diagnosis & Workup
[89]
Nakamura MM, Zaslavsky AM, Toomey SL et al.. “Pediatric Readmissions After Hospitalizations for Lower Respiratory Infections.” Pediatrics (2017). PMID: 28771405 ↗
L2OTHERCited in: Diagnosis & Workup
[90]
Farber HJ, Buckwold FJ, Lachman B et al.. “Observed Effectiveness of Palivizumab for 29-36-Week Gestation Infants.” Pediatrics (2016). PMID: 27432850 ↗
L2OTHERCited in: Diagnosis & Workup
[91]
Perramon-Malavez A, Hermosilla E, Coma E et al.. “Effectiveness of Nirsevimab Immunoprophylaxis Against Respiratory Syncytial Virus-related Outcomes in Hospital Care Settings: A Seasonal Cohort Study of Infants in Catalonia, Spain.” The Pediatric infectious disease journal (2025). PMID: 39823640 ↗
L2COHORTCited in: Diagnosis & Workup, Prognosis & Natural History, Prevention, Screening & Surveillance
[92]
Mahant S, Parkin PC, Thavam T et al.. “Rates in Bronchiolitis Hospitalization, Intensive Care Unit Use, Mortality, and Costs From 2004 to 2018.” JAMA pediatrics (2022). PMID: 34928313 ↗
L2OTHERCited in: Diagnosis & Workup, Prognosis & Natural History
[93]
Beck AF, Florin TA, Campanella S et al.. “Geographic Variation in Hospitalization for Lower Respiratory Tract Infections Across One County.” JAMA pediatrics (2015). PMID: 26192102 ↗
L2OTHERCited in: Diagnosis & Workup, Special Populations
[94]
Principi T, Coates AL, Parkin PC et al.. “Effect of Oxygen Desaturations on Subsequent Medical Visits in Infants Discharged From the Emergency Department With Bronchiolitis.” JAMA pediatrics (2016). PMID: 26928704 ↗
L2OTHERCited in: Diagnosis & Workup, Prognosis & Natural History, Special Populations
[95]
Elliott SA, Cyrkot S, Scott SD et al.. “Enhancing parental health knowledge through digital knowledge mobilisation tools: a randomised controlled trial and qualitative study.” BMJ paediatrics open (2026). PMID: 42173560 ↗
L1RCTCited in: Diagnosis & Workup, Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization, Long-term & Definitive Management, History and Evolution of Treatment, Prognosis & Natural History, Special Populations
[96]
Assad Z, Romain AS, Aupiais C et al.. “Nirsevimab and Hospitalization for RSV Bronchiolitis.” The New England journal of medicine (2024). PMID: 38986058 ↗
L3OTHERCited in: Diagnosis & Workup
[97]
Marin JR, Hollander MAG, Ray KN et al.. “Low-Value Diagnostic Imaging in Children with Medicaid.” The Journal of pediatrics (2021). PMID: 33556364 ↗
L2OTHERCited in: Diagnosis & Workup, Special Populations
[98]
Bucholz EM, Gay JC, Hall M et al.. “Timing and Causes of Common Pediatric Readmissions.” The Journal of pediatrics (2018). PMID: 29887387 ↗
L2OTHERCited in: Diagnosis & Workup
[99]
Rolfsjord LB, Bakkeheim E, Berents TL et al.. “Morning Salivary Cortisol in Young Children: Reference Values and the Effects of Age, Sex, and Acute Bronchiolitis.” The Journal of pediatrics (2017). PMID: 28284475 ↗
L2OTHERCited in: Diagnosis & Workup
[100]
Hartmann F, Fiori HH, Ramos Garcia PC et al.. “Surfactant deficiency in infants with severe acute viral bronchiolitis.” The Journal of pediatrics (2014). PMID: 24657121 ↗
L3OTHERCited in: Diagnosis & Workup
[101]
Loveys K, Borland ML, Oakley E et al.. “Investigations for Bronchiolitis in Infants: An Overview of Reviews and Systematic Review of Primary Studies.” Pediatric pulmonology (2026). PMID: 41906981 ↗
L2SR_OBSCited in: Diagnosis & Workup
[102]
Loveys K, Haskell L, Cotterell E et al.. “Efficacy and Safety of Azithromycin in Infants With Bronchiolitis: A Systematic Review and Meta-Analysis.” Acta paediatrica (Oslo, Norway : 1992) (2025). PMID: 41074495 ↗
L1SR_OBSCited in: Diagnosis & Workup
[103]
Bowyer SA, Bryant WA, Key D et al.. “Machine learning forecasting for COVID-19 pandemic-associated effects on paediatric respiratory infections.” Archives of disease in childhood (2022). PMID: 35948401 ↗
L3OTHERCited in: Diagnosis & Workup
[104]
Griffiths B, Riphagen S, Lillie J. “Management of severe bronchiolitis: impact of NICE guidelines.” Archives of disease in childhood (2018). PMID: 30472669 ↗
L4OTHERCited in: Diagnosis & Workup
[105]
Cathie K, Sutcliffe AG, Bandi S et al.. “Priorities for child health research across the UK and Ireland.” Archives of disease in childhood (2021). PMID: 34716174 ↗
L5OTHERCited in: Diagnosis & Workup, Special Populations
[106]
Fitzpatrick T, McNally JD, Stukel TA et al.. “Palivizumab's real-world effectiveness: a population-based study in Ontario, Canada, 1993-2017.” Archives of disease in childhood (2020). PMID: 32859612 ↗
L2OTHERCited in: Diagnosis & Workup
[107]
van Hasselt TJ, Singham B, Bassett E et al.. “Oxygen saturation thresholds in bronchiolitis: examining admissions.” Archives of disease in childhood (2019). PMID: 31462433 ↗
L2OTHERCited in: Diagnosis & Workup
[108]
Marlais M, Evans J, Abrahamson E. “Clinical predictors of admission in infants with acute bronchiolitis.” Archives of disease in childhood (2011). PMID: 21339199 ↗
L2OTHERCited in: Diagnosis & Workup, Complications
[109]
Manti S, Gambadauro A, Stocchero M et al.. “Application of machine learning to predict bronchiolitis severity in children: a single-centre retrospective cohort study.” European journal of pediatrics (2026). PMID: 42171780 ↗
L3COHORTCited in: Diagnosis & Workup
[110]
Shanklin A, Rivera EAT, Pollack MM et al.. “The Association of Iatrogenic Withdrawal With Opioid and Benzodiazepine Weaning in Children With Bronchiolitis: A Single-Center, Retrospective Cohort Study, 2012-2022.” Critical care explorations (2026). PMID: 41823985 ↗
L3COHORTCited in: Diagnosis & Workup, Prognosis & Natural History
[111]
Spurling GK, Fonseka K, Doust J et al.. “Antibiotics for bronchiolitis in children.” The Cochrane database of systematic reviews (2007). PMID: 17253545 ↗
L1SR_OBSCited in: Diagnosis & Workup, Complications
[112]
Beggs S, Wong ZH, Kaul S et al.. “High-flow nasal cannula therapy for infants with bronchiolitis.” The Cochrane database of systematic reviews (2014). PMID: 24442856 ↗
L1SR_OBSCited in: Diagnosis & Workup, Complications
[113]
Gill PJ, Anwar MR, Kornelsen E et al.. “Parenteral versus enteral fluid therapy for children hospitalised with bronchiolitis.” The Cochrane database of systematic reviews (2021). PMID: 34852398 ↗
L1SR_OBSCited in: Diagnosis & Workup, Complications, Prognosis & Natural History, Special Populations
[114]
McCallum GB, Plumb EJ, Morris PS et al.. “Antibiotics for persistent cough or wheeze following acute bronchiolitis in children.” The Cochrane database of systematic reviews (2017). PMID: 28828759 ↗
L1SR_OBSCited in: Diagnosis & Workup
[115]
Mayfield S, Jauncey-Cooke J, Hough JL et al.. “High-flow nasal cannula therapy for respiratory support in children.” The Cochrane database of systematic reviews (2014). PMID: 24604698 ↗
L1SR_OBSCited in: Diagnosis & Workup
[116]
Blom D, Ermers M, Bont L et al.. “Inhaled corticosteroids during acute bronchiolitis in the prevention of post-bronchiolitic wheezing.” The Cochrane database of systematic reviews (2007). PMID: 17253528 ↗
L1SR_OBSCited in: Diagnosis & Workup
[117]
Blom DJ, Ermers M, Bont L et al.. “WITHDRAWN: Inhaled corticosteroids during acute bronchiolitis in the prevention of post-bronchiolitic wheezing.” The Cochrane database of systematic reviews (2011). PMID: 21249665 ↗
L1SR_OBSCited in: Diagnosis & Workup, History and Evolution of Treatment
[118]
Falsey AR. “Human metapneumovirus infection in adults.” The Pediatric infectious disease journal (2008). PMID: 18820584 ↗
L5OTHERCited in: Diagnosis & Workup, Complications, Prognosis & Natural History, Special Populations
[119]
Zaharov T, Franck KT, Nygaard U et al.. “Chronic Lung Disease after Hospitalization with Adenovirus or Respiratory Syncytial Virus.” The Pediatric infectious disease journal (2025). PMID: 40215198 ↗
L3OTHERCited in: Diagnosis & Workup
[120]
Sippy R, Prado EO, Pizarro Fajardo F et al.. “Medically Attended Outpatient Coronavirus Infections in Ecuadorean Children During the 20 Months Preceding Countrywide Lockdown Related to the SARS-CoV-2 Pandemic of 2020.” The Pediatric infectious disease journal (2020). PMID: 32773657 ↗
L2OTHERCited in: Diagnosis & Workup
[121]
Calvo C, García-García ML, Pozo F et al.. “Clinical characteristics of human bocavirus infections compared with other respiratory viruses in Spanish children.” The Pediatric infectious disease journal (2008). PMID: 18574440 ↗
L2OTHERCited in: Diagnosis & Workup
[122]
Kooiman L, Blankespoor F, Hofman R et al.. “High-flow oxygen therapy in moderate to severe bronchiolitis: a randomised controlled trial.” Archives of disease in childhood (2023). PMID: 36941030 ↗
L1RCTCited in: Severity Grading, Staging & Risk Stratification, Long-term & Definitive Management, History and Evolution of Treatment, Prognosis & Natural History, Special Populations
[123]
Schondelmeyer AC, Dewan ML, Brady PW et al.. “Cardiorespiratory and Pulse Oximetry Monitoring in Hospitalized Children: A Delphi Process.” Pediatrics (2020). PMID: 32680879 ↗
L5REVIEW_NARRATIVECited in: Severity Grading, Staging & Risk Stratification
[124]
Fernandes RM, Plint AC, Terwee CB et al.. “Validity of bronchiolitis outcome measures.” Pediatrics (2015). PMID: 25986025 ↗
L4OTHERCited in: Severity Grading, Staging & Risk Stratification, Prognosis & Natural History, Special Populations
[125]
Hinderstein S, Aragona E, Loyal J. “Parent Perspectives on Nirsevimab for Their Newborn.” Pediatrics (2024). PMID: 39587878 ↗
L5OTHERCited in: Severity Grading, Staging & Risk Stratification, Prevention, Screening & Surveillance
[126]
Synhorst DC, Johnson MB, Bettenhausen JL et al.. “Room Costs for Common Pediatric Hospitalizations and Cost-Reducing Quality Initiatives.” Pediatrics (2020). PMID: 32366609 ↗
L2OTHERCited in: Severity Grading, Staging & Risk Stratification
[127]
Bourgeois FT, Monuteaux MC, Stack AM et al.. “Variation in emergency department admission rates in US children's hospitals.” Pediatrics (2014). PMID: 25113291 ↗
L2OTHERCited in: Severity Grading, Staging & Risk Stratification
[128]
Fieldston ES, Shah SS, Hall M et al.. “Resource utilization for observation-status stays at children's hospitals.” Pediatrics (2013). PMID: 23669520 ↗
L2OTHERCited in: Severity Grading, Staging & Risk Stratification
[129]
Heneghan JA, Goodman DM, Ramgopal S. “Hospitalizations at United States Children's Hospitals and Severity of Illness by Neighborhood Child Opportunity Index.” The Journal of pediatrics (2022). PMID: 36270394 ↗
L2OTHERCited in: Severity Grading, Staging & Risk Stratification, Complications
[130]
Vo P, Koppel C, Espinola JA et al.. “Vitamin D Status at the Time of Hospitalization for Bronchiolitis and Its Association with Disease Severity.” The Journal of pediatrics (2018). PMID: 30243543 ↗
L2OTHERCited in: Severity Grading, Staging & Risk Stratification
[131]
Milési C, Requirand A, Douillard A et al.. “Assessment of Peak Inspiratory Flow in Young Infants with Acute Viral Bronchiolitis: Physiological Basis for Initial Flow Setting in Patients Supported with High-Flow Nasal Cannula.” The Journal of pediatrics (2020). PMID: 33333115 ↗
L4OTHERCited in: Severity Grading, Staging & Risk Stratification
[132]
Gordon B, Nyiro JU, Nair H et al.. “External Validation of Pediatric Pneumonia and Bronchiolitis Risk Scores to Predict Mortality in Children Hospitalized in Kenya: A Retrospective Cohort Study.” The Journal of infectious diseases (2026). PMID: 40692486 ↗
L2COHORTCited in: Severity Grading, Staging & Risk Stratification, Prognosis & Natural History
[133]
Moraa I, Sturman N, McGuire T et al.. “Heliox for croup in children.” The Cochrane database of systematic reviews (2013). PMID: 24318607 ↗
L1SR_OBSCited in: Severity Grading, Staging & Risk Stratification
[134]
Ozeki S, Oshiro M, Fukumi D et al.. “Change Over Time in Seasonality and Severity of Children Hospitalized With Respiratory Syncytial Virus Infection in Japan.” The Pediatric infectious disease journal (2022). PMID: 35544732 ↗
L4OTHERCited in: Severity Grading, Staging & Risk Stratification
[135]
McClintock J, Odom-Mabey AR, Kebere N et al.. “Postmortem Nasopharyngeal Microbiome Analysis of Zambian Infants With and Without Respiratory Syncytial Virus Disease: A Nested Case Control Study.” The Pediatric infectious disease journal (2023). PMID: 37093853 ↗
L3OTHERCited in: Severity Grading, Staging & Risk Stratification, Prognosis & Natural History
[136]
Erkkola R, Turunen R, Räisänen K et al.. “Rhinovirus C Is Associated With Severe Wheezing and Febrile Respiratory Illness in Young Children.” The Pediatric infectious disease journal (2020). PMID: 31876616 ↗
L2OTHERCited in: Severity Grading, Staging & Risk Stratification, History and Evolution of Treatment
[137]
Abu Raya B, Bamberger E, Kassis I et al.. “Bordetella pertussis infection attenuates clinical course of acute bronchiolitis.” The Pediatric infectious disease journal (2013). PMID: 23429556 ↗
L3OTHERCited in: Severity Grading, Staging & Risk Stratification
[138]
Guerrero-Del-Cueto F, Lobato-Lopez S, Lozano-Duran D et al.. “Assessing the Impact of Nirsevimab Immunization on RSV Bronchiolitis Hospital Admissions and Their Severity: A Case-Control Study and Comparison With Pre- and Post-COVID-19 Seasons in a Tertiary Pediatric Hospital.” Pediatric pulmonology (2025). PMID: 40662491 ↗
L3CASE_CONTROLCited in: Severity Grading, Staging & Risk Stratification
[139]
Hermoso PS, Conejo MM, Alejandre C et al.. “Long-Term Functional Outcomes After Pediatric Intensive Care Unit Admission for Bronchiolitis: A 12-Month Cohort Study.” Children (Basel, Switzerland) (2026). PMID: 42194162 ↗
L2COHORTCited in: Severity Grading, Staging & Risk Stratification
[140]
Oweidat M, Alra'e M, Allawi R et al.. “Association of high-flow nasal cannula (HFNC) therapy with intensive care unit admission and mechanical ventilation use in respiratory syncytial virus-positive bronchiolitis in pediatric patients: a retrospective single-center cohort study.” BMC pulmonary medicine (2026). PMID: 41987094 ↗
L2COHORTCited in: Severity Grading, Staging & Risk Stratification
[141]
Ito M, Nakano A, Arimoto Y et al.. “Clinical characteristics and severity of primary ciliary dyskinesia caused by large homozygous deletion including exons 1-4 of DRC1: A multicenter retrospective cohort study.” Respiratory investigation (2026). PMID: 41570615 ↗
L2COHORTCited in: Severity Grading, Staging & Risk Stratification
[142]
Roqué-Figuls M, Giné-Garriga M, Granados Rugeles C et al.. “Chest physiotherapy for acute bronchiolitis in paediatric patients between 0 and 24 months old.” The Cochrane database of systematic reviews (2023). PMID: 37010196 ↗
L1REVIEW_NARRATIVECited in: Severity Grading, Staging & Risk Stratification
[143]
Silver AH, Esteban-Cruciani N, Azzarone G et al.. “3% Hypertonic Saline Versus Normal Saline in Inpatient Bronchiolitis: A Randomized Controlled Trial.” Pediatrics (2015). PMID: 26553190 ↗
L1RCTCited in: Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization, Long-term & Definitive Management, History and Evolution of Treatment
[144]
Alansari K, Toaimah FH, Almatar DH et al.. “Monoclonal Antibody Treatment of RSV Bronchiolitis in Young Infants: A Randomized Trial.” Pediatrics (2019). PMID: 30760509 ↗
L1RCTCited in: Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization, Long-term & Definitive Management, History and Evolution of Treatment, Prognosis & Natural History
[145]
Chidini G, Piastra M, Marchesi T et al.. “Continuous positive airway pressure with helmet versus mask in infants with bronchiolitis: an RCT.” Pediatrics (2015). PMID: 25780074 ↗
L1RCTCited in: Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization, Long-term & Definitive Management, Complications
[146]
Haskell L, Tavender EJ, Wilson CL et al.. “Effectiveness of Targeted Interventions on Treatment of Infants With Bronchiolitis: A Randomized Clinical Trial.” JAMA pediatrics (2021). PMID: 33843971 ↗
L1RCTCited in: Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization, Long-term & Definitive Management, History and Evolution of Treatment, Growth, Development & Nutrition Impact, Prognosis & Natural History, Special Populations
[147]
Angoulvant F, Bellêttre X, Milcent K et al.. “Effect of Nebulized Hypertonic Saline Treatment in Emergency Departments on the Hospitalization Rate for Acute Bronchiolitis: A Randomized Clinical Trial.” JAMA pediatrics (2017). PMID: 28586918 ↗
L1RCTCited in: Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization, Long-term & Definitive Management, History and Evolution of Treatment, Special Populations
[148]
Florin TA, Shaw KN, Kittick M et al.. “Nebulized hypertonic saline for bronchiolitis in the emergency department: a randomized clinical trial.” JAMA pediatrics (2014). PMID: 24862342 ↗
L1RCTCited in: Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization, Long-term & Definitive Management, History and Evolution of Treatment, Prognosis & Natural History, Special Populations
[149]
Plint AC, Johnson DW, Patel H et al.. “Epinephrine and dexamethasone in children with bronchiolitis.” The New England journal of medicine (2009). PMID: 19439742 ↗
L1RCTCited in: Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization, Long-term & Definitive Management, History and Evolution of Treatment, Prognosis & Natural History, Special Populations
[150]
Kepreotes E, Whitehead B, Attia J et al.. “High-flow warm humidified oxygen versus standard low-flow nasal cannula oxygen for moderate bronchiolitis (HFWHO RCT): an open, phase 4, randomised controlled trial.” Lancet (London, England) (2017). PMID: 28161016 ↗
L1RCTCited in: Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization, Long-term & Definitive Management, History and Evolution of Treatment, Prognosis & Natural History, Special Populations
[151]
Alansari K, Toaimah FH, Khalafalla H et al.. “Caffeine for the Treatment of Apnea in Bronchiolitis: A Randomized Trial.” The Journal of pediatrics (2016). PMID: 27189681 ↗
L1RCTCited in: Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization, Long-term & Definitive Management, History and Evolution of Treatment, Prognosis & Natural History, Special Populations
[152]
Kuzik BA, Al-Qadhi SA, Kent S et al.. “Nebulized hypertonic saline in the treatment of viral bronchiolitis in infants.” The Journal of pediatrics (2007). PMID: 17719935 ↗
L1RCTCited in: Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization, Long-term & Definitive Management, Prognosis & Natural History
[153]
Tie SW, Hall GL, Peter S et al.. “Home oxygen for children with acute bronchiolitis.” Archives of disease in childhood (2008). PMID: 18927148 ↗
L1RCTCited in: Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization, Long-term & Definitive Management, Complications, Special Populations
[154]
Zomer-Kooijker K, van der Ent CK, Ermers MJ et al.. “Lack of long-term effects of high-dose inhaled beclomethasone for respiratory syncytial virus bronchiolitis: a randomized placebo-controlled trial.” The Pediatric infectious disease journal (2014). PMID: 24346594 ↗
L1RCTCited in: Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization, Long-term & Definitive Management, History and Evolution of Treatment, Growth, Development & Nutrition Impact, Prognosis & Natural History
[155]
Backman K, Helminen M, Kekäläinen E et al.. “Working group summary of the 2023 full update of the Finnish national guidelines for paediatric lower respiratory tract infections.” Acta paediatrica (Oslo, Norway : 1992) (2024). PMID: 39487609 ↗
L1GUIDELINECited in: Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization, Long-term & Definitive Management
[156]
Riese J, Porter T, Fierce J et al.. “Clinical Outcomes of Bronchiolitis After Implementation of a General Ward High Flow Nasal Cannula Guideline.” Hospital pediatrics (2017). PMID: 28292850 ↗
L2GUIDELINECited in: Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization
[157]
Tapiainen T, Aittoniemi J, Immonen J et al.. “Finnish guidelines for the treatment of laryngitis, wheezing bronchitis and bronchiolitis in children.” Acta paediatrica (Oslo, Norway : 1992) (2015). PMID: 26295564 ↗
L1GUIDELINECited in: Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization
[158]
Maya M, Rameshkumar R, Selvan T et al.. “High-Flow Nasal Cannula Versus Nasal Prong Bubble Continuous Positive Airway Pressure in Children With Moderate to Severe Acute Bronchiolitis: A Randomized Controlled Trial.” Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies (2024). PMID: 38639564 ↗
L1RCTCited in: Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization, Long-term & Definitive Management
[159]
Schuh S, Coates AL, Sweeney J et al.. “Nasal Suctioning Therapy Among Infants With Bronchiolitis Discharged Home From the Emergency Department: A Randomized Clinical Trial.” JAMA network open (2023). PMID: 37856126 ↗
L1RCTCited in: Acute & Emergency Management: Neonatal Resuscitation & Pediatric Stabilization
[160]
Alansari K, Sakran M, Davidson BL et al.. “Oral dexamethasone for bronchiolitis: a randomized trial.” Pediatrics (2013). PMID: 24043283 ↗
L1RCTCited in: Long-term & Definitive Management, History and Evolution of Treatment
[161]
Jacobs JD, Foster M, Wan J et al.. “7% Hypertonic saline in acute bronchiolitis: a randomized controlled trial.” Pediatrics (2013). PMID: 24344111 ↗
L1RCTCited in: Long-term & Definitive Management, History and Evolution of Treatment
[162]
Chowdhury MM, McKenzie SA, Pearson CC et al.. “Heliox therapy in bronchiolitis: phase III multicenter double-blind randomized controlled trial.” Pediatrics (2013). PMID: 23509160 ↗
L1RCTCited in: Long-term & Definitive Management, History and Evolution of Treatment
[163]
Bajaj L, Turner CG, Bothner J. “A randomized trial of home oxygen therapy from the emergency department for acute bronchiolitis.” Pediatrics (2006). PMID: 16510641 ↗
L1RCTCited in: Long-term & Definitive Management, History and Evolution of Treatment, Complications
[164]
Elliott SA, Gaudet LA, Fernandes RM et al.. “Comparative Efficacy of Bronchiolitis Interventions in Acute Care: A Network Meta-analysis.” Pediatrics (2021). PMID: 33893229 ↗
L1SR_OBSCited in: Long-term & Definitive Management, Special Populations
[165]
McCulloh R, Koster M, Ralston S et al.. “Use of Intermittent vs Continuous Pulse Oximetry for Nonhypoxemic Infants and Young Children Hospitalized for Bronchiolitis: A Randomized Clinical Trial.” JAMA pediatrics (2015). PMID: 26322819 ↗
L1RCTCited in: Long-term & Definitive Management, History and Evolution of Treatment
[166]
Franklin D, Babl FE, Schlapbach LJ et al.. “A Randomized Trial of High-Flow Oxygen Therapy in Infants with Bronchiolitis.” The New England journal of medicine (2018). PMID: 29562151 ↗
L1RCTCited in: Long-term & Definitive Management, History and Evolution of Treatment
[167]
Skjerven HO, Hunderi JO, Brügmann-Pieper SK et al.. “Racemic adrenaline and inhalation strategies in acute bronchiolitis.” The New England journal of medicine (2013). PMID: 23758233 ↗
L1RCTCited in: Long-term & Definitive Management, History and Evolution of Treatment
[168]
Cunningham S, Rodriguez A, Adams T et al.. “Oxygen saturation targets in infants with bronchiolitis (BIDS): a double-blind, randomised, equivalence trial.” Lancet (London, England) (2015). PMID: 26382998 ↗
L1RCTCited in: Long-term & Definitive Management, History and Evolution of Treatment
[169]
Al-Ansari K, Sakran M, Davidson BL et al.. “Nebulized 5% or 3% hypertonic or 0.9% saline for treating acute bronchiolitis in infants.” The Journal of pediatrics (2010). PMID: 20646715 ↗
L1RCTCited in: Long-term & Definitive Management, History and Evolution of Treatment
[170]
Ralston S, Roohi M. “A randomized, controlled trial of nasal phenylephrine in infants hospitalized for bronchiolitis.” The Journal of pediatrics (2008). PMID: 18657831 ↗
L1RCTCited in: Long-term & Definitive Management, History and Evolution of Treatment
[171]
Kim CK, Choi J, Kim HB et al.. “A randomized intervention of montelukast for post-bronchiolitis: effect on eosinophil degranulation.” The Journal of pediatrics (2010). PMID: 20171653 ↗
L1RCTCited in: Long-term & Definitive Management, History and Evolution of Treatment
[172]
Pinto LA, Pitrez PM, Luisi F et al.. “Azithromycin therapy in hospitalized infants with acute bronchiolitis is not associated with better clinical outcomes: a randomized, double-blinded, and placebo-controlled clinical trial.” The Journal of pediatrics (2012). PMID: 22748516 ↗
L1RCTCited in: Long-term & Definitive Management
[173]
Valencia-Ramos J, Ochoa Sangrador C, García M et al.. “Impact of different nebulisation systems on patient comfort in bronchiolitis: a randomised controlled cross-over trial.” Archives of disease in childhood (2022). PMID: 36162958 ↗
L1RCTCited in: Long-term & Definitive Management, History and Evolution of Treatment, Prognosis & Natural History
[174]
Bueno Campaña M, Olivares Ortiz J, Notario Muñoz C et al.. “High flow therapy versus hypertonic saline in bronchiolitis: randomised controlled trial.” Archives of disease in childhood (2014). PMID: 24521787 ↗
L1RCTCited in: Long-term & Definitive Management, History and Evolution of Treatment
[175]
Thia LP, McKenzie SA, Blyth TP et al.. “Randomised controlled trial of nasal continuous positive airways pressure (CPAP) in bronchiolitis.” Archives of disease in childhood (2007). PMID: 17344251 ↗
L1RCTCited in: Long-term & Definitive Management, History and Evolution of Treatment, Complications
[176]
Lin J, Zhang Y, Xiong L et al.. “High-flow nasal cannula therapy for children with bronchiolitis: a systematic review and meta-analysis.” Archives of disease in childhood (2019). PMID: 30655267 ↗
L1SR_OBSCited in: Long-term & Definitive Management
[177]
Livni G, Rachmel A, Marom D et al.. “A randomized, double-blind study examining the comparative efficacies and safety of inhaled epinephrine and nasal decongestant in hospitalized infants with acute bronchiolitis.” The Pediatric infectious disease journal (2010). PMID: 19907355 ↗
L1RCTCited in: Long-term & Definitive Management, History and Evolution of Treatment
[178]
Semple MG, Donohue C, Price L et al.. “Endotracheal surfactant for infants with life-threatening bronchiolitis (BESS): a randomised, blinded, sham-controlled, phase 2 trial.” The Lancet. Respiratory medicine (2026). PMID: 41875912 ↗
L1RCTCited in: Long-term & Definitive Management, History and Evolution of Treatment, Growth, Development & Nutrition Impact
[179]
Kaushik M, Bhalla K. “Comparison of 3 different flow rates of high-flow nasal cannula (1 L/kg/min versus 2 L/kg/min versus 3 L/kg/min) in management of children admitted with bronchiolitis: a randomized controlled trial.” European journal of pediatrics (2025). PMID: 41430493 ↗
L1RCTCited in: Long-term & Definitive Management, History and Evolution of Treatment, Complications
[180]
Kulkarni PS, Zaman K, Desai SA et al.. “Safety and immunogenicity of a reduced-dose inactivated poliovirus vaccine versus a full-dose inactivated poliovirus vaccine in infants in Bangladesh: a double-blind, non-inferiority, randomised, controlled, phase 3 trial.” The Lancet. Infectious diseases (2025). PMID: 40505670 ↗
L1RCTCited in: Long-term & Definitive Management
[181]
Combret Y, Machefert M, Couet M et al.. “Effect of a prolonged slow expiration technique on 24-h food intake in children hospitalized for moderate bronchiolitis: a randomized controlled trial.” Italian journal of pediatrics (2024). PMID: 39334411 ↗
L1RCTCited in: Long-term & Definitive Management
[182]
Gadomski AM, Scribani MB. “Bronchodilators for bronchiolitis.” The Cochrane database of systematic reviews (2014). PMID: 24937099 ↗
L1SR_OBSCited in: Long-term & Definitive Management
[183]
Jat KR, Chawla D. “Surfactant therapy for bronchiolitis in critically ill infants.” The Cochrane database of systematic reviews (2015). PMID: 26299681 ↗
L1SR_OBSCited in: Long-term & Definitive Management, Complications, Prognosis & Natural History, Special Populations
[184]
Gadomski AM, Brower M. “Bronchodilators for bronchiolitis.” The Cochrane database of systematic reviews (2010). PMID: 21154348 ↗
L1SR_OBSCited in: Long-term & Definitive Management
[185]
Fernandes RM, Bialy LM, Vandermeer B et al.. “Glucocorticoids for acute viral bronchiolitis in infants and young children.” The Cochrane database of systematic reviews (2013). PMID: 23733383 ↗
L1SR_OBSCited in: Long-term & Definitive Management
[186]
Jat KR, Mathew JL. “Continuous positive airway pressure (CPAP) for acute bronchiolitis in children.” The Cochrane database of systematic reviews (2019). PMID: 30701528 ↗
L1SR_OBSCited in: Long-term & Definitive Management
[187]
Liet JM, Ducruet T, Gupta V et al.. “Heliox inhalation therapy for bronchiolitis in infants.” The Cochrane database of systematic reviews (2010). PMID: 20393951 ↗
L1SR_OBSCited in: Long-term & Definitive Management
[188]
Liet JM, Ducruet T, Gupta V et al.. “Heliox inhalation therapy for bronchiolitis in infants.” The Cochrane database of systematic reviews (2015). PMID: 26384333 ↗
L1SR_OBSCited in: Long-term & Definitive Management
[189]
Jat KR, Chawla D. “Surfactant therapy for bronchiolitis in critically ill infants.” The Cochrane database of systematic reviews (2012). PMID: 22972138 ↗
L1SR_OBSCited in: Long-term & Definitive Management, Prognosis & Natural History, Special Populations
[190]
Hogeling M, Adams S, Wargon O. “A randomized controlled trial of propranolol for infantile hemangiomas.” Pediatrics (2011). PMID: 21788220 ↗
L1RCTCited in: History and Evolution of Treatment, Growth, Development & Nutrition Impact
[191]
Amirav I, Luder AS, Kruger N et al.. “A double-blind, placebo-controlled, randomized trial of montelukast for acute bronchiolitis.” Pediatrics (2008). PMID: 18984650 ↗
L1RCTCited in: History and Evolution of Treatment
[192]
Mallory MD, Shay DK, Garrett J et al.. “Bronchiolitis management preferences and the influence of pulse oximetry and respiratory rate on the decision to admit.” Pediatrics (2003). PMID: 12509594 ↗
L5RCTCited in: History and Evolution of Treatment
[193]
Mahant S, Wahi G, Bayliss A et al.. “Intermittent vs Continuous Pulse Oximetry in Hospitalized Infants With Stabilized Bronchiolitis: A Randomized Clinical Trial.” JAMA pediatrics (2021). PMID: 33646286 ↗
L1RCTCited in: History and Evolution of Treatment
[194]
Coon ER, Destino LA, Greene TH et al.. “Comparison of As-Needed and Scheduled Posthospitalization Follow-up for Children Hospitalized for Bronchiolitis: The Bronchiolitis Follow-up Intervention Trial (BeneFIT) Randomized Clinical Trial.” JAMA pediatrics (2020). PMID: 32628250 ↗
L1RCTCited in: History and Evolution of Treatment, Prognosis & Natural History, Special Populations
[195]
Corneli HM, Zorc JJ, Mahajan P et al.. “A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis.” The New England journal of medicine (2007). PMID: 17652648 ↗
L1RCTCited in: History and Evolution of Treatment
[196]
Wainwright C, Altamirano L, Cheney M et al.. “A multicenter, randomized, double-blind, controlled trial of nebulized epinephrine in infants with acute bronchiolitis.” The New England journal of medicine (2003). PMID: 12840089 ↗
L1RCTCited in: History and Evolution of Treatment
[197]
Roosevelt G, Sheehan K, Grupp-Phelan J et al.. “Dexamethasone in bronchiolitis: a randomised controlled trial.” Lancet (London, England) (1996). PMID: 8709687 ↗
L1RCTCited in: History and Evolution of Treatment
[198]
Swingler GH, Hussey GD, Zwarenstein M. “Randomised controlled trial of clinical outcome after chest radiograph in ambulatory acute lower-respiratory infection in children.” Lancet (London, England) (1998). PMID: 9482294 ↗
L1RCTCited in: History and Evolution of Treatment
[199]
Schuh S, Canny G, Reisman JJ et al.. “Nebulized albuterol in acute bronchiolitis.” The Journal of pediatrics (1990). PMID: 2213394 ↗
L1RCTCited in: History and Evolution of Treatment
[200]
Klassen TP, Rowe PC, Sutcliffe T et al.. “Randomized trial of salbutamol in acute bronchiolitis.” The Journal of pediatrics (1991). PMID: 2019938 ↗
L1RCTCited in: History and Evolution of Treatment
[201]
Klassen TP, Sutcliffe T, Watters LK et al.. “Dexamethasone in salbutamol-treated inpatients with acute bronchiolitis: a randomized, controlled trial.” The Journal of pediatrics (1997). PMID: 9042119 ↗
L1RCTCited in: History and Evolution of Treatment
[202]
Patel H, Gouin S, Platt RW. “Randomized, double-blind, placebo-controlled trial of oral albuterol in infants with mild-to-moderate acute viral bronchiolitis.” The Journal of pediatrics (2003). PMID: 12756382 ↗
L1RCTCited in: History and Evolution of Treatment
[203]
Hemming VG, Prince GA, Rodriguez W et al.. “Respiratory syncytial virus infections and intravenous gamma-globulins.” The Pediatric infectious disease journal (1988). PMID: 3041354 ↗
L5RCTCited in: History and Evolution of Treatment
[204]
Fox GF, Everard ML, Marsh MJ et al.. “Randomised controlled trial of budesonide for the prevention of post-bronchiolitis wheezing.” Archives of disease in childhood (1999). PMID: 10086941 ↗
L1RCTCited in: History and Evolution of Treatment
[205]
Barry W, Cockburn F, Cornall R et al.. “Ribavirin aerosol for acute bronchiolitis.” Archives of disease in childhood (1986). PMID: 3524473 ↗
L1RCTCited in: History and Evolution of Treatment
[206]
Webb MS, Martin JA, Cartlidge PH et al.. “Chest physiotherapy in acute bronchiolitis.” Archives of disease in childhood (1985). PMID: 3907510 ↗
L2RCTCited in: History and Evolution of Treatment
[207]
Cade A, Brownlee KG, Conway SP et al.. “Randomised placebo controlled trial of nebulised corticosteroids in acute respiratory syncytial viral bronchiolitis.” Archives of disease in childhood (2000). PMID: 10648365 ↗
L1RCTCited in: History and Evolution of Treatment
[208]
Menendez C, Sunyer J, Ventura PJ et al.. “Malaria infection does not appear to modify the risk of bronchiolitis early in life.” The Pediatric infectious disease journal (2002). PMID: 12005090 ↗
L2RCTCited in: History and Evolution of Treatment
[209]
Chipps BE, Sullivan WF, Portnoy JM. “Alpha-2A-interferon for treatment of bronchiolitis caused by respiratory syncytial virus.” The Pediatric infectious disease journal (1993). PMID: 8414778 ↗
L1RCTCited in: History and Evolution of Treatment
[210]
Tsai XC, Yao ZH, Chou SW et al.. “Taiwan consensus on pulmonary chronic graft-versus-host disease: A joint statement from the Taiwan Society of Blood and Marrow Transplantation (TBMT) and Taiwan Society of Pulmonary and Critical Care Medicine (TSPCCM).” British journal of haematology (2025). PMID: 40926299 ↗
L1GUIDELINECited in: History and Evolution of Treatment
[211]
Kattan M. “Epidemiologic evidence of increased airway reactivity in children with a history of bronchiolitis.” The Journal of pediatrics (1999). PMID: 10431133 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[212]
Nagakumar P, Doull I. “Current therapy for bronchiolitis.” Archives of disease in childhood (2012). PMID: 22734014 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[213]
Fuller HL, Del Mar CB. “WITHDRAWN: Immunoglobulin treatment for respiratory syncytial virus infection.” The Cochrane database of systematic reviews (2010). PMID: 20824840 ↗
L1SR_OBSCited in: History and Evolution of Treatment, Prognosis & Natural History, Special Populations
[214]
Ventre K, Haroon M, Davison C. “WITHDRAWN. Surfactant therapy for bronchiolitis in critically ill infants.” The Cochrane database of systematic reviews (2010). PMID: 20091572 ↗
L1SR_OBSCited in: History and Evolution of Treatment, Special Populations
[215]
Patel H, Platt R, Lozano JM. “WITHDRAWN: Glucocorticoids for acute viral bronchiolitis in infants and young children.” The Cochrane database of systematic reviews (2008). PMID: 18254063 ↗
L1SR_OBSCited in: History and Evolution of Treatment
[216]
Soto-Martínez ME, Acuña Cordero R, Parra-Buitrago A et al.. “Respiratory Syncytial Virus in Pediatrics: Update on Epidemiology, Management, Long-term Consequences and Prevention. Consensus From Asociación Latinoamericana de Tórax (ALAT) 2025.” Archivos de bronconeumologia (2026). PMID: 41714249 ↗
L1GUIDELINECited in: History and Evolution of Treatment
[217]
Cravéreau O, Bourbonne V, Vaugier L et al.. “[Recommendations on the prevention and management of radiation-induced lung injury from the Association francophone pour les soins oncologiques de support and the Société française de radiothérapie oncologique].” Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique (2025). PMID: 40774102 ↗
L1GUIDELINECited in: History and Evolution of Treatment
[218]
Perch M, Corris P, Lordan J et al.. “A European multicentre, randomised controlled trial of pirfenidone in bronchiolitis obliterans syndrome after bilateral lung transplantation.” The European respiratory journal (2026). PMID: 41232942 ↗
L1RCTCited in: History and Evolution of Treatment
[219]
Darras BT, Masson R, Mazurkiewicz-Bełdzińska M et al.. “Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls.” The New England journal of medicine (2021). PMID: 34320287 ↗
L4OTHERCited in: History and Evolution of Treatment
[220]
King MS, Eisenberg R, Newman JH et al.. “Constrictive bronchiolitis in soldiers returning from Iraq and Afghanistan.” The New England journal of medicine (2011). PMID: 21774710 ↗
L4OTHERCited in: History and Evolution of Treatment
[221]
Dakhama A, Lee YM, Gelfand EW. “Virus-induced airway dysfunction: pathogenesis and biomechanisms.” The Pediatric infectious disease journal (2005). PMID: 16378041 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[222]
Welliver RC. “Respiratory syncytial virus and other respiratory viruses.” The Pediatric infectious disease journal (2003). PMID: 12671447 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[223]
Xanthouli P, Schatz A, Bergner R et al.. “[Management of pulmonary and cardiovascular comorbidities in rheumatological diseases].” Zeitschrift fur Rheumatologie (2025). PMID: 40736566 ↗
L1GUIDELINECited in: History and Evolution of Treatment
[224]
Bebia Z, Dieussaert I, Jose L et al.. “Randomized, placebo-controlled phase 3 trial evaluating safety, immunogenicity, and reactogenicity of RSVPreF3-Mat in high-risk pregnant women and their infants.” Human vaccines & immunotherapeutics (2026). PMID: 41766205 ↗
L1RCTCited in: History and Evolution of Treatment, Complications, Prevention, Screening & Surveillance
[225]
Harris J, Crulli B, Latour JM et al.. “Effect of Morphine on Respiratory Drive in Infants With Acute Viral Bronchiolitis Receiving Neurally Adjusted Ventilatory Assist.” Respiratory care (2025). PMID: 41626651 ↗
L1RCTCited in: History and Evolution of Treatment
[226]
Cozzi G, Sovtic A, Garelli D et al.. “SARS-CoV-2-related bronchiolitis: a multicentre international study.” Archives of disease in childhood (2023). PMID: 37130726 ↗
L3OTHERCited in: History and Evolution of Treatment, Prognosis & Natural History, Special Populations
[227]
Jartti T, Aakula M, Mansbach JM et al.. “Hospital length-of-stay is associated with rhinovirus etiology of bronchiolitis.” The Pediatric infectious disease journal (2014). PMID: 25222302 ↗
L2OTHERCited in: History and Evolution of Treatment
[228]
Grimaldi M, Gouyon B, Michaut F et al.. “Severe respiratory syncytial virus bronchiolitis: epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasia.” The Pediatric infectious disease journal (2004). PMID: 15626942 ↗
L2OTHERCited in: History and Evolution of Treatment
[229]
de Betue CT, van Waardenburg DA, Deutz NE et al.. “Increased protein-energy intake promotes anabolism in critically ill infants with viral bronchiolitis: a double-blind randomised controlled trial.” Archives of disease in childhood (2011). PMID: 21673183 ↗
L1RCTCited in: Growth, Development & Nutrition Impact
[230]
Arias AV, Lucas DJ, Shafi NI. “Respiratory Syncytial Virus Bronchiolitis Complicated by Necrotizing Enterocolitis: A Case Series.” Pediatrics (2021). PMID: 33824182 ↗
L4CASE_REPORTCited in: Growth, Development & Nutrition Impact, Complications
[231]
Sweet DG, Turner MA, Straňák Z et al.. “A first-in-human clinical study of a new SP-B and SP-C enriched synthetic surfactant (CHF5633) in preterm babies with respiratory distress syndrome.” Archives of disease in childhood. Fetal and neonatal edition (2017). PMID: 28465315 ↗
L2TRIAL_NONRANDOMCited in: Growth, Development & Nutrition Impact, Complications
[232]
Rivas-Calderon M, Yamazaki-Nakashimada MA, Orozco-Covarrubias L et al.. “Bronchiolitis Obliterans With Anti-Epiplakin Antibodies in a Boy With Paraneoplastic Pemphigus.” Pediatrics (2022). PMID: 35118492 ↗
L4OTHERCited in: Growth, Development & Nutrition Impact
[233]
Guttmann A, Razzaq A, Lindsay P et al.. “Development of measures of the quality of emergency department care for children using a structured panel process.” Pediatrics (2006). PMID: 16818556 ↗
L5OTHERCited in: Growth, Development & Nutrition Impact
[234]
Carroll KN, Gebretsadik T, Griffin MR et al.. “Maternal asthma and maternal smoking are associated with increased risk of bronchiolitis during infancy.” Pediatrics (2007). PMID: 17545377 ↗
L3OTHERCited in: Growth, Development & Nutrition Impact, Complications
[235]
Pinto RA, Arredondo SM, Bono MR et al.. “T helper 1/T helper 2 cytokine imbalance in respiratory syncytial virus infection is associated with increased endogenous plasma cortisol.” Pediatrics (2006). PMID: 16618789 ↗
L4OTHERCited in: Growth, Development & Nutrition Impact
[236]
Hasegawa K, Mansbach JM, Bochkov YA et al.. “Association of Rhinovirus C Bronchiolitis and Immunoglobulin E Sensitization During Infancy With Development of Recurrent Wheeze.” JAMA pediatrics (2019). PMID: 30933255 ↗
L2OTHERCited in: Growth, Development & Nutrition Impact, Special Populations
[237]
Smyth RL, Openshaw PJ. “Bronchiolitis.” Lancet (London, England) (2006). PMID: 16860701 ↗
L5REVIEW_NARRATIVECited in: Growth, Development & Nutrition Impact
[238]
Adderson E, Allison KJ, Branum K et al.. “Intranasal Sendai Virus Vaccination of Seropositive Children 1 to 2 Years of Age in a Phase I Clinical Trial Boosts Immune Responses Toward Human Parainfluenza Virus Type 1.” Vaccines (2025). PMID: 40333329 ↗
L4TRIAL_NONRANDOMCited in: Growth, Development & Nutrition Impact, Prevention, Screening & Surveillance
[239]
Liem JJ, Huq SI, Ekuma O et al.. “Transient tachypnea of the newborn may be an early clinical manifestation of wheezing symptoms.” The Journal of pediatrics (2007). PMID: 17586187 ↗
L3OTHERCited in: Growth, Development & Nutrition Impact
[240]
Palomar LM, Nogee LM, Sweet SC et al.. “Long-term outcomes after infant lung transplantation for surfactant protein B deficiency related to other causes of respiratory failure.” The Journal of pediatrics (2006). PMID: 17011330 ↗
L3OTHERCited in: Growth, Development & Nutrition Impact, Complications
[241]
Jotterand Chaparro C, Bertoni Maluf VA, Pabion C et al.. “The effectiveness of high versus lower enteral protein intake, considering energy intake, on clinical outcomes in critically ill children: A systematic review and meta-analysis.” Clinical nutrition (Edinburgh, Scotland) (2025). PMID: 41109033 ↗
L1SR_OBSCited in: Growth, Development & Nutrition Impact
[242]
Rojas-McKenzie M, Fraga JP, Iturriaga C et al.. “Early Use of Proton Pump Inhibitors Increases Risk of Upper Respiratory Tract Infections in Children: A Birth Cohort Study.” Pediatric pulmonology (2026). PMID: 42360697 ↗
L2COHORTCited in: Growth, Development & Nutrition Impact, Special Populations
[243]
Li L, Shen K, Chen Q et al.. “Association of early-life human rhinovirus and respiratory syncytial virus infections with childhood asthma: a cohort study in Suzhou, China.” BMJ open (2026). PMID: 42161543 ↗
L3COHORTCited in: Growth, Development & Nutrition Impact, Complications, Prognosis & Natural History, Special Populations
[244]
Schwarze J. “Lung dendritic cells in respiratory syncytial virus bronchiolitis.” The Pediatric infectious disease journal (2008). PMID: 18820586 ↗
L5OTHERCited in: Growth, Development & Nutrition Impact, Prevention, Screening & Surveillance
[245]
Hegde S, Prodhan P. “Serious air leak syndrome complicating high-flow nasal cannula therapy: a report of 3 cases.” Pediatrics (2013). PMID: 23382446 ↗
L4CASE_REPORTCited in: Complications
[246]
Duarte-Salles T, Vizcaya D, Pistillo A et al.. “Thirty-Day Outcomes of Children and Adolescents With COVID-19: An International Experience.” Pediatrics (2021). PMID: 34049958 ↗
L3OTHERCited in: Complications
[247]
Cohen E, Rodean J, Diong C et al.. “Low-Value Diagnostic Imaging Use in the Pediatric Emergency Department in the United States and Canada.” JAMA pediatrics (2019). PMID: 31157877 ↗
L3OTHERCited in: Complications, Prognosis & Natural History
[248]
Oakley E, Bata S, Rengasamy S et al.. “Nasogastric Hydration in Infants with Bronchiolitis Less Than 2 Months of Age.” The Journal of pediatrics (2016). PMID: 27522439 ↗
L3OTHERCited in: Complications
[249]
Xu B, Cao L, Shang Y et al.. “Low-dose versus high-dose methylprednisolone for children with severe Mycoplasma pneumoniae pneumonia (MCMP): A randomized controlled trial.” Pediatric investigation (2025). PMID: 40969290 ↗
L1RCTCited in: Complications, Prognosis & Natural History
[250]
Sayed MS, Elgendy MA, Gamil N et al.. “Efficacy and safety of a single dose of nirsevimab against respiratory syncytial virus infection in infants: a meta-analysis and time-to-event analysis.” Italian journal of pediatrics (2025). PMID: 41469925 ↗
L1SR_OBSCited in: Complications
[251]
Broughton S, Bhat R, Roberts A et al.. “Diminished lung function, RSV infection, and respiratory morbidity in prematurely born infants.” Archives of disease in childhood (2005). PMID: 16188957 ↗
L2OTHERCited in: Complications
[252]
Graham S, Sartorius B, Snelling T et al.. “A retrospective cohort study and spatial analysis of climate and community-level determinants of respiratory syncytial virus notifications among Queensland infants, prior to the introduction of the RSV mother and infant protection program (RSV-MIPP) immunisation initiative.” BMC public health (2026). PMID: 41566313 ↗
L2COHORTCited in: Complications
[253]
Çoksüer F, Öztürk GK, Ocak E et al.. “Pulmonary outcomes of pediatric patients with postinfectious bronchiolitis obliterans treated with pulse methylprednisolone and intravenous immunoglobulin: a single-center cohort study.” European journal of pediatrics (2025). PMID: 40773144 ↗
L2COHORTCited in: Complications
[254]
Spurling GK, Doust J, Del Mar CB et al.. “Antibiotics for bronchiolitis in children.” The Cochrane database of systematic reviews (2011). PMID: 21678346 ↗
L1SR_OBSCited in: Complications
[255]
Farley R, Spurling GK, Eriksson L et al.. “Antibiotics for bronchiolitis in children under two years of age.” The Cochrane database of systematic reviews (2014). PMID: 25300167 ↗
L1SR_OBSCited in: Complications
[256]
Nicolai A, Frassanito A, Nenna R et al.. “Risk Factors for Virus-induced Acute Respiratory Tract Infections in Children Younger Than 3 Years and Recurrent Wheezing at 36 Months Follow-Up After Discharge.” The Pediatric infectious disease journal (2017). PMID: 27798551 ↗
L2OTHERCited in: Complications
[257]
Richard N, Komurian-Pradel F, Javouhey E et al.. “The impact of dual viral infection in infants admitted to a pediatric intensive care unit associated with severe bronchiolitis.” The Pediatric infectious disease journal (2008). PMID: 18277932 ↗
L3OTHERCited in: Complications
[258]
Lawrence J, Walpola R, Boyce SL et al.. “Home Care for Bronchiolitis: A Systematic Review.” Pediatrics (2022). PMID: 36065737 ↗
L2SR_OBSCited in: Prognosis & Natural History, Special Populations
[259]
Harrison W, Angoulvant F, House S et al.. “Hypertonic Saline in Bronchiolitis and Type I Error: A Trial Sequential Analysis.” Pediatrics (2018). PMID: 30115731 ↗
L1SR_OBSCited in: Prognosis & Natural History
[260]
Hester G, Nickel AJ, Watson D et al.. “Use of a Clinical Guideline and Orderset to Reduce Hospital Admissions for Croup.” Pediatrics (2022). PMID: 35970819 ↗
L2REVIEW_NARRATIVECited in: Prognosis & Natural History
[261]
Sandweiss DR, Mundorff MB, Hill T et al.. “Decreasing hospital length of stay for bronchiolitis by using an observation unit and home oxygen therapy.” JAMA pediatrics (2013). PMID: 23479000 ↗
L2OTHERCited in: Prognosis & Natural History
[262]
de Sonnaville ESV, Kӧnigs M, Aarnoudse-Moens CSH et al.. “Long-Term Follow-Up of Daily Life Functioning After Pediatric Intensive Care Unit Admission.” The Journal of pediatrics (2023). PMID: 37187287 ↗
L2OTHERCited in: Prognosis & Natural History, Special Populations
[263]
Florin TA, Byczkowski T, Ruddy RM et al.. “Variation in the management of infants hospitalized for bronchiolitis persists after the 2006 American Academy of Pediatrics bronchiolitis guidelines.” The Journal of pediatrics (2014). PMID: 25015578 ↗
L2OTHERCited in: Prognosis & Natural History, Special Populations
[264]
Montejo M, Paniagua N, Saiz-Hernando C et al.. “Initiatives to reduce treatments in bronchiolitis in the emergency department and primary care.” Archives of disease in childhood (2019). PMID: 31666241 ↗
L2OTHERCited in: Prognosis & Natural History, Special Populations
[265]
Liu TW, Huang SY, Chou CM et al.. “The Association Between the Surgical Timing for Congenital Malformation of Lung and Asthma Prevalence-A Nationwide Cohort Study.” Pediatric pulmonology (2025). PMID: 40734376 ↗
L2COHORTCited in: Prognosis & Natural History
[266]
Jat KR, Dsouza JM, Mathew JL. “Continuous positive airway pressure (CPAP) for acute bronchiolitis in children.” The Cochrane database of systematic reviews (2022). PMID: 35377462 ↗
L2SR_OBSCited in: Prognosis & Natural History, Special Populations
[267]
Ventre K, Haroon M, Davison C. “Surfactant therapy for bronchiolitis in critically ill infants.” The Cochrane database of systematic reviews (2006). PMID: 16856080 ↗
L1SR_OBSCited in: Prognosis & Natural History, Special Populations
[268]
Fuller H, Del Mar C. “Immunoglobulin treatment for respiratory syncytial virus infection.” The Cochrane database of systematic reviews (2006). PMID: 17054220 ↗
L1SR_OBSCited in: Prognosis & Natural History, Special Populations
[269]
Bergroth E, Aakula M, Korppi M et al.. “Post-bronchiolitis Use of Asthma Medication: A Prospective 1-year Follow-up Study.” The Pediatric infectious disease journal (2016). PMID: 26658529 ↗
L2OTHERCited in: Prognosis & Natural History
[270]
Fouzas S, Priftis KN, Anthracopoulos MB. “Pulse oximetry in pediatric practice.” Pediatrics (2011). PMID: 21930554 ↗
L5REVIEW_NARRATIVECited in: Special Populations
[271]
Andina Martínez D, Claret Teruel G, Gijón Mediavilla M et al.. “Nirsevimab and Acute Bronchiolitis Episodes in Pediatric Emergency Departments.” Pediatrics (2024). PMID: 39257372 ↗
L2OTHERCited in: Special Populations
[272]
Ralston SL, House SA, Harrison W et al.. “The Evolution of Quality Benchmarks for Bronchiolitis.” Pediatrics (2021). PMID: 34462342 ↗
L2OTHERCited in: Special Populations
[273]
Lenglart L, Titomanlio L, Bognar Z et al.. “Surge of Pediatric Respiratory Tract Infections after the COVID-19 Pandemic and the Concept of "Immune Debt".” The Journal of pediatrics (2024). PMID: 39579868 ↗
L2OTHERCited in: Special Populations, Prevention, Screening & Surveillance
[274]
Mansbach JM, Qi YS, Espinola JA et al.. “Late Pre-term Infants with Severe Bronchiolitis and Risk of Asthma by Age 5 Years.” The Journal of pediatrics (2021). PMID: 34599916 ↗
L2OTHERCited in: Special Populations
[275]
Cunningham S, McMurray A. “Observational study of two oxygen saturation targets for discharge in bronchiolitis.” Archives of disease in childhood (2011). PMID: 21388970 ↗
L2OTHERCited in: Special Populations
[276]
García-Garcia ML, González-Carrasco E, Quevedo S et al.. “Clinical and Virological Characteristics of Early and Moderate Preterm Infants Readmitted With Viral Respiratory Infections.” The Pediatric infectious disease journal (2015). PMID: 25923427 ↗
L2OTHERCited in: Special Populations
[277]
Bryan MA, Hofstetter AM, deHart MP et al.. “Vaccination Status and Resource Use During Hospital Visits for Respiratory Illnesses.” Pediatrics (2019). PMID: 31624218 ↗
L2OTHERCited in: Prevention, Screening & Surveillance
[278]
Choudhuri JA, Ogden LG, Ruttenber AJ et al.. “Effect of altitude on hospitalizations for respiratory syncytial virus infection.” Pediatrics (2006). PMID: 16452353 ↗
L2OTHERCited in: Prevention, Screening & Surveillance
[279]
Calvo C, Alcolea S, Casas I et al.. “A 14-year Prospective Study of Human Coronavirus Infections in Hospitalized Children: Comparison With Other Respiratory Viruses.” The Pediatric infectious disease journal (2020). PMID: 32453196 ↗
L2COHORTCited in: Prevention, Screening & Surveillance
[280]
Fusco E, Loiodice M, Romero A et al.. “Effectiveness of Nirsevimab in Preventing Respiratory Syncytial Virus-related Burden: A Test-negative Case-control Study in Infants With Bronchiolitis in Lombardy Region, Italy.” The Pediatric infectious disease journal (2025). PMID: 41104905 ↗
L3CASE_CONTROLCited in: Prevention, Screening & Surveillance
[281]
Lukac CD, Simms B, Kwong GPS et al.. “Hospitalizations for all-cause pediatric acute respiratory diseases in Alberta, Canada, before, during, and after the COVID-19 pandemic: a population-level retrospective cohort study from 2010 to 2024.” Lancet regional health. Americas (2025). PMID: 40260184 ↗
L2COHORTCited in: Prevention, Screening & Surveillance
[282]
Marouk A, Verrat B, Pontais I et al.. “Effectiveness of nirsevimab in reducing hospitalizations in emergency departments due to bronchiolitis among infants under 3 months: a retrospective study.” European journal of pediatrics (2025). PMID: 40044918 ↗
L2COHORTCited in: Prevention, Screening & Surveillance
[283]
Bar-On ES, Goldberg E, Hellmann S et al.. “Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB).” The Cochrane database of systematic reviews (2012). PMID: 22513932 ↗
L1SR_OBSCited in: Prevention, Screening & Surveillance
[284]
Phijffer EWEM, Wildenbeest JG, Brouwer CNM et al.. “The Full Burden of RSV-related Pediatric Intensive Care Unit Admissions During Infancy: A Prospective National Study (BRICK Study).” The Pediatric infectious disease journal (2025). PMID: 40359239 ↗
L2OTHERCited in: Prevention, Screening & Surveillance